View Filing Data

Print Document View Excel Document

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2019	Mar. 02, 2020	Jun. 30, 2019
Document Information [Line Items]
Entity Registrant Name	LEMAITRE VASCULAR INC
Entity Central Index Key	0001158895
Trading Symbol	lmat
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		20,178,506
Entity Public Float			$ 261,775,368
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.01 par value per share

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 11,786	$ 26,318
Short-term marketable securities	20,895	21,668
Accounts receivable, net of allowances of $522 at December 31, 2019, and $399 at December 31, 2018	16,572	15,721
Inventory and other deferred costs	39,527	27,388
Prepaid expenses and other current assets	3,312	2,922
Total current assets	92,092	94,017
Property and equipment, net	14,854	14,102
Right-of-use leased assets	15,208
Goodwill	39,951	29,868
Other intangibles, net	24,893	13,692
Deferred tax assets	1,084	1,215
Other assets	259	194
Total assets	188,341	153,088
Liabilities and stockholders’ equity
Accounts payable	2,604	1,732
Accrued expenses	14,014	15,847
Acquisition-related obligations	2,476	2,179
Lease liabilities - short-term	1,757
Total current liabilities	20,851	19,758
Lease liabilities - long-term	13,955
Deferred tax liabilities	1,179	484
Other long-term liabilities	4,215	2,611
Total liabilities	40,200	22,853
Stockholders’ equity:
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 21,678,927 shares at December 31, 2019, and 21,110,224 shares at December 31, 2018	217	211
Additional paid-in capital	105,934	98,442
Retained earnings	57,029	45,831
Accumulated other comprehensive loss	(4,007)	(3,900)
Treasury stock, at cost; 1,522,035 shares at December 31, 2019 and 1,501,511 shares at December 31, 2018	(11,032)	(10,349)
Total stockholders’ equity	148,141	130,235
Total liabilities and stockholders’ equity	$ 188,341	$ 153,088

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounts receivable, allowances	$ 522	$ 399
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	3,000,000	3,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	37,000,000	37,000,000
Common stock, shares issued (in shares)	21,678,927	21,110,224
Treasury stock, at cost (in shares)	1,522,035	1,501,511

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net sales	$ 117,232	$ 105,568	$ 100,867
Cost of sales	37,379	31,629	30,170
Gross profit	79,853	73,939	70,697
Sales and marketing	30,339	27,318	25,948
General and administrative	19,055	17,689	17,010
Research and development	9,276	8,197	6,636
Gain on acquisitions and divestitures		(7,474)
Total operating expenses	58,670	45,730	49,594
Income from operations	21,183	28,209	21,103
Other income (expense):
Interest income	698	631	179
Interest expense		(2)	(21)
Foreign currency loss	(202)	(394)	(155)
Income before income taxes	21,679	28,444	21,106
Provision for income taxes	3,745	5,501	3,929
Net income	$ 17,934	$ 22,943	$ 17,177
Earnings per share of common stock:
Basic (in dollars per share)	$ 0.91	$ 1.18	$ 0.91
Diluted (in dollars per share)	$ 0.88	$ 1.13	$ 0.86
Weighted-average shares outstanding:
Basic (in shares)	19,813	19,426	18,961
Diluted (in shares)	20,326	20,242	20,033
Cash dividends declared per common share (in dollars per share)	$ 0.34	$ 0.28	$ 0.22

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net income	$ 17,934	$ 22,943	$ 17,177
Other comprehensive income (loss):
Foreign currency translation adjustment, net	(234)	(1,626)	2,294
Unrealized gain (loss) on short-term marketable securities	127	15
Total other comprehensive income (loss)	(107)	(1,611)	2,294
Comprehensive income	$ 17,827	$ 21,332	$ 19,471

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

AOCI Attributable to Parent [Member]

Treasury Stock [Member]

Total

Balance (in shares) at Dec. 31, 2016

20,040,348

1,452,810

Balance at Dec. 31, 2016

$ 200

$ 85,378

$ 15,335

$ (4,583)

$ (8,830)

$ 87,500

Net income

17,177

Other comprehensive income

2,294

Issuance of common stock for stock options exercised (in shares)

635,503

Issuance of common stock for stock options exercised

$ 7

5,493

5,500

Vested restricted stock units (in shares)

69,190

Vested restricted stock units

Stock-based compensation expense

2,256

Repurchase of common stock at cost (in shares)

27,291

Repurchase of common stock at cost

$ (778)

(778)

Common stock cash dividend paid

(4,179)

Balance (in shares) at Dec. 31, 2017

20,745,041

1,480,101

Balance at Dec. 31, 2017

$ 207

93,127

28,333

(2,289)

$ (9,608)

109,770

Net income

22,943

Other comprehensive income

(1,611)

Issuance of common stock for stock options exercised (in shares)

303,379

Issuance of common stock for stock options exercised

$ 4

2,966

2,970

Vested restricted stock units (in shares)

61,804

Vested restricted stock units

Stock-based compensation expense

2,349

Repurchase of common stock at cost (in shares)

21,410

Repurchase of common stock at cost

$ (741)

(741)

Common stock cash dividend paid

(5,445)

Balance (in shares) at Dec. 31, 2018

21,110,224

1,501,511

Balance at Dec. 31, 2018

$ 211

98,442

45,831

(3,900)

$ (10,349)

130,235

Net income

17,934

Other comprehensive income

(107)

$ (107)

Issuance of common stock for stock options exercised (in shares)

509,693

^[1]

Issuance of common stock for stock options exercised

$ 6

4,850

$ 4,856

Vested restricted stock units (in shares)

59,010

Vested restricted stock units

Stock-based compensation expense

2,642

Repurchase of common stock at cost (in shares)

20,524

Repurchase of common stock at cost

$ (683)

(683)

Common stock cash dividend paid

(6,736)

Balance (in shares) at Dec. 31, 2019

21,678,927

1,522,035

Balance at Dec. 31, 2019

$ 217

$ 105,934

$ 57,029

$ (4,007)

$ (11,032)

$ 148,141

[1]	The aggregate intrinsic value of shares exercised represents the difference between the exercise price and the closing price of our stock on the date of exercise.

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating activities
Net income	$ 17,934	$ 22,943	$ 17,177
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	5,416	4,324	4,055
Stock-based compensation	2,642	2,349	2,256
Fair value adjustments to contingent consideration obligations	171	(29)	106
Provision for doubtful accounts and allowances	388	264	230
Provision for inventory write-downs	747	671	396
Provision (benefit) for deferred income taxes	824	(2,152)	300
Gain on acquisitions and divestitures		(7,474)
Foreign currency transaction gain	(57)	259	(29)
Changes in operating assets and liabilities:
Accounts receivable	(1,301)	(1,283)	(1,507)
Inventory and other deferred costs	(11,335)	(4,262)	(1,352)
Prepaid expenses and other assets	(654)	(418)	(288)
Accounts payable and other liabilities	(596)	4,314	1,524
Net cash provided by operating activities	14,179	19,506	22,868
Investing activities
Purchases of property and equipment	(3,761)	(3,054)	(6,417)
Payments related to acquisitions	(21,240)	(12,282)
Purchases of short-term marketable securities	(22,699)	(19,619)	(22,541)
Proceeds from sales of marketable securities	23,600	20,500
Proceeds from divestitures		7,400
Net cash used in investing activities	(24,100)	(7,055)	(28,958)
Financing activities
Payment of deferred acquisition consideration	(2,059)	(1,199)	(463)
Proceeds from issuance of common stock	4,856	2,969	5,500
Purchase of treasury stock	(683)	(741)	(778)
Common stock cash dividend paid	(6,736)	(5,445)	(4,179)
Net cash provided by (used in) financing activities	(4,622)	(4,416)	80
Effect of exchange rate changes on cash and cash equivalents	11	(813)	818
Net increase (decrease) in cash and cash equivalents	(14,532)	7,222	(5,192)
Cash and cash equivalents at beginning of year	26,318	19,096	24,288
Cash and cash equivalents at end of year	$ 11,786	$ 26,318	$ 19,096

Note 1 - Significant Accounting Policies and Related Matters

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Significant Accounting Policies [Text Block]

Significant Accounting Policies and Related Matters

Description of Business

Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. We operate in a

single

segment in which our principal product lines include the following: anastomotic clips, angioscopes, balloon catheters, biologic vascular grafts, biologic vascular patches, carotid shunts, polyester vascular grafts, powered phlebectomy devices, radiopaque marking tape, remote endarterectomy devices, surgical glue and valvulotomes. Our offices are located in Burlington, Massachusetts; Chandler, Arizona; Fox River Grove, Illinois; Vaughan, Canada; Hereford, England; Sulzbach, Germany; Milan, Italy; Madrid, Spain; Saint-Etienne, France; North Melbourne, Australia; Tokyo, Japan; Shanghai, China and Singapore.

Consolidation and Basis of Presentation

Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries, LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, LeMaitre Vascular Pty Ltd, Bio Nova International Pty Ltd, LeMaitre Vascular, Ltd., LeMaitre Medical Technology (Shanghai) Co. Ltd, LeMaitre Cardial SAS and LeMaitre Vascular Singapore Pte Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.

Foreign Currency Translation

Balance sheet accounts of foreign subsidiaries are translated into U.S. dollars at year-end exchange rates. Operating accounts are translated at average exchange rates for each year. Net translation gains or losses are adjusted directly to a separate component of other comprehensive income (loss) within stockholders’ equity. Foreign exchange transaction gains (losses), substantially all of which relate to intercompany activity between us and our foreign subsidiaries, are included in other income (expense) in the accompanying consolidated statements of operations.

Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to bad debts, inventory and other deferred costs, intangible assets, sales returns and discounts, and income taxes are reviewed on an ongoing basis and updated as appropriate. Actual results could differ from those estimates.

Revenue Recognition

Our revenue is derived primarily from the sale of disposable or implantable devices used during vascular surgery. We sell primarily directly to hospitals and to a lesser extent to distributors, as described below, and, during the periods presented in our consolidated financial statements, entered into consigned inventory arrangements with either hospitals or distributors on a limited basis. With the acquisition of the RestoreFlow allograft business, we also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. These revenues are recognized when services have been provided and the tissue has been shipped to the customer, provided all other revenue recognition criteria discussed in the succeeding paragraph have been met.

January

2018

we adopted the provisions of ASU

2014

09,

Revenue from Contracts with Customers (Topic

606

)

. We used the modified retrospective method of adoption under which the comparative information was

not

restated and will continue to be reported under the standard in effect for those periods. The adoption of this standard was

not

material to our financial statements and there was

cumulative effect adjustment to the opening balance of retained earnings required. The core principle of Topic

606

is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard explains that to achieve the core principle, an entity should take the following actions:

Step

Identify the contract with a customer

Step

Identify the performance obligations in the contract

Step

Determine the transaction price

Step

Allocate the transaction price

Step

Recognize revenue when or as the entity satisfies a performance obligation

Revenue is recognized when or as a company satisfies a performance obligation by transferring a promised good or service to a customer (which is when the customer obtains control of that good or service). In instances in which shipping and handling activities are performed after a customer takes control of the goods (such as when title passes upon shipment from our dock), we have made the policy election allowed under Topic

606

to account for these activities as fulfillment costs and

not

as performance obligations.

We generally reference customer purchase orders to determine the existence of a contract. Orders that are

not

accompanied by a purchase order are confirmed with the customer either in writing or verbally. The purchase orders or similar correspondence, once accepted, identify the performance obligations as well as the transaction price, and otherwise outline the rights and obligations of each party. We allocate the transaction price of each contract among the performance obligations in accordance with the pricing of each item specified on the purchase order, which is in turn based on standalone selling prices per our published price lists. In cases where we discount products or provide certain items free of charge, we allocate the discount proportionately to all performance obligations, unless it can be demonstrated that the discount should be allocated entirely to

one

or more, but

not

all, of the performance obligations.

We recognize revenue, net of allowances for returns and discounts, fees paid to group purchasing organizations, and any sales and value added taxes required to be invoiced, which we have elected to exclude from the measurement of the transaction price as allowed by the standard, at the time of shipment (taking into consideration contractual shipping terms), or in the case of consigned inventory, when it is consumed. Shipment is the point at which control of the product and title passes to our customers, and at which LeMaitre Vascular has a present right to receive payment for the goods.

Below is a disaggregation of our revenue by major geographic area, which is among the primary categorizations used by management in evaluating financial performance, for the periods indicated (in thousands):

	Year ended December 31,
	2019		2018
Americas	$	69,359	$	63,649
Europe, Middle East and Africa	$	39,480		35,319
Asia/Pacific Rim	$	8,393		6,600
Total	$	117,232	$	105,568

Except as discussed in Note

we do

not

carry any contract assets or contract liabilities, as there are generally

unbilled amounts due from customers under contracts for which we have partially satisfied performance obligations, or amounts received from customers for which we have

not

satisfied performance obligations. We satisfy our performance obligations under revenue contracts within a very short time period from receipt of the orders, and payments from customers are typically received within

days of fulfillment of the orders, except in certain geographies such as Spain and Italy where the payment cycle is customarily longer. Accordingly, there is

significant financing component to our revenue contracts. Additionally, we have elected as a policy that incremental costs (such as commissions) incurred to obtain contracts are expensed as incurred, due to the short-term nature of the contracts.

Customers returning products

may

be entitled to full or partial credit based on the condition and timing of the return. To be accepted, a returned product must be unopened (if sterile), unadulterated, and undamaged, must have at least

months remaining prior to its expiration date, or

twelve

months for our hospital customers in Europe, and generally be returned within

days of shipment. These return policies apply to sales to both hospitals and distributors. The amount of products returned to us, either for exchange or credit, has

not

been material. Nevertheless, we provide for an allowance for future sales returns based on historical return experience, which requires judgment. Our cost of replacing defective products has

not

been material and is accounted for at the time of replacement.

Research and Development Expense

Research and development costs, principally salaries, laboratory testing, and supplies, are expensed as incurred and also include royalty payments associated with licensed and acquired intellectual property.

Shipping and Handling Costs

Shipping and handling fees paid by customers are recorded within net sales, with the related expense recorded in cost of sales.

Advertising Costs

Advertising costs are expensed as incurred and are included as a component of sales and marketing expense in the accompanying consolidated statements of operations. Advertising costs are as follows:

	Year ended December 31,
	2019		2018		2017
			(in thousands)

Advertising expense	$	286	$	299	$	305

Cash and Cash Equivalents

We consider all highly liquid instruments purchased with maturity dates of

days or less to be cash equivalents. Cash and cash equivalents are primarily invested in money market funds. These amounts are stated at cost, which approximates fair value.

Short-term Marketable Securitie

Our short-term marketable securities are available-for-sale securities carried at fair value, with unrealized gains and losses recorded in other comprehensive income.

Concentrations of Credit Risk

Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent highly liquid investments with maturities of

days or less at the date of purchase. Credit risk related to cash and cash equivalents are limited based on the creditworthiness of the financial institutions at which these funds are held. We maintain cash balances in several banks. Accounts located in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to

$250,000.

Certain of our account balances exceed the FDIC limit. Cash balances held outside the United States totaled approximately

$9.0

million as of

December

31,

2019.

Our accounts receivable are with customers based in the United States and internationally. Accounts receivable generally are due within

days of invoice and are stated at amounts due from customers, net of an allowance for doubtful accounts and sales returns, other than in certain European markets where longer payment terms are customary and

may

range from

240

days. We perform ongoing credit evaluations of the financial condition of our customers and adjust credit limits based upon payment history and the current creditworthiness of the customers, as determined by a review of their current credit information. We continuously monitor aging reports, collections, and payments from customers, and maintain a provision for estimated credit losses based upon historical experience and any specific customer collection issues we identify.

We closely monitor outstanding receivables for potential collection risks, including those that

may

arise from economic conditions, in both the U.S. and international economies. Our European sales to government-owned or supported customers such as hospitals, distributors and agents, in Southern Europe, specifically Italy and Spain

may

be subject to significant payment delays due to government austerity measures impacting funding and payment practices. As of

December

31,

2019

our receivables in Italy and Spain totaled

$1.0

million and

$0.8

million, respectively. Receivables balances with certain publicly-owned hospitals and government supported customers in these countries can accumulate over a period of time and then subsequently be settled as large lump sum payments. While we believe our allowance for doubtful accounts in these countries is adequate as of

December

31,

2019,

if significant changes were to occur in the payment practices of these European governments or if government funding becomes unavailable, we

may

not

be able to collect on receivables due to us from these customers and our write offs of uncollectible amounts

may

increase.

We write off accounts receivable when they become uncollectible. Such credit losses have historically been within our expectations and allowances. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We review our allowance for doubtful accounts on a monthly basis and all past due balances are reviewed individually for collectability. The provision for the allowance for doubtful accounts is recorded in general and administrative expenses. The following is a summary of our allowance for doubtful accounts and sales returns:

	Balance at		Additions		Deductions		Balance at
	Beginning		(recoveries) charged		from		End of
	of Period		to Income		Reserves		Period
	(in thousands)
Allowance for doubtful accounts and sales returns:
Year ended December 31, 2019	$	399	$	388	$	265		522
Year ended December 31, 2018		349		264		214		399
Year ended December 31, 2017		258		230		139		349

Fair Value of Financial Instruments

Our financial instruments include cash and cash equivalents, short-term marketable securities, accounts receivable and trade payables. The fair value of these instruments approximates their carrying value based upon their short-term nature or variable rates of interest. Unrealized gains and losses on our short-term marketable securities are recorded in other comprehensive income and were

not

material to our consolidated financial statements for the year ended

December 31, 2019.

Inventory and Other Deferred Costs

Inventory and Other Deferred Costs consists of finished products, work-in-process, raw materials and costs deferred in connection with human tissue cryopreservation services of our RestoreFlow allograft business. We value inventory and other deferred costs at the lower of cost or market value. Cost includes materials, labor and manufacturing overhead and is determined using the

first

-in,

first

-out (FIFO) method. On a quarterly basis, we review inventory quantities on hand and analyze the provision for excess and obsolete inventory based primarily on product expiration dating and our estimated sales forecast, which is based on sales history and anticipated future demand. Our estimates of future product demand

may

not

be accurate, and we

may

understate or overstate the provision required for excess and obsolete inventory. Accordingly, any significant unanticipated changes in demand could have a significant impact on the value of our inventory and results of operations.

Property and Equipment

Property and equipment are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using straight-line method as follows:

Description	Useful Life (Years)
Computers and equipment	3	–	5
Machinery and equipment	3	–	10
Leasehold improvements	The shorter of its useful life or lease term

Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from the accounts and any gain or loss is reflected in the statement of operations.

Valuation of Business Combinations

We assign the value of the consideration transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. We assess the fair value of assets, including intangible assets, using a variety of methods and are usually performed by an independent appraiser who measures fair value from the perspective of a market participant.

Acquisitions have been accounted for using the acquisition method, and the acquired companies’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. Acquisition transaction costs have been recorded in general and administrative expenses, and are expensed as incurred. Allocation of the purchase price for acquisitions is based on estimates of the fair value of the net assets acquired and, for acquisitions completed within the past year, is subject to adjustment upon finalization of the purchase price allocation.

Our acquisitions have historically been made at prices above the fair value of the acquired assets, resulting in goodwill, due to expectations of synergies of combining the businesses. These synergies include use of our existing commercial infrastructure to expand sales of the acquired businesses’ products, use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of our products, and the elimination of redundant facilities, functions and staffing.

Contingent Consideration

Contingent consideration for acquisitions is recognized at the date of acquisition, based on the fair value at that date, and then re-measured periodically through adjustments to net income.

Impairment of Long-lived Assets

We review our long-lived assets (primarily property and equipment and intangible assets) subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that

may

indicate impairment include, but are

not

limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall, or an adverse action or assessment by a regulator. If an impairment indicator exists, we test the intangible asset for recoverability. We record impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Impairment is measured based on the fair market value of the affected asset using discounted cash flows.

Goodwill

Goodwill represents the amount of consideration paid in connection with business acquisitions in excess of the fair value of assets acquired and liabilities assumed. Goodwill is evaluated for impairment annually or more frequently if indicators of impairment are present or changes in circumstances suggest that an impairment

may

exist. We evaluate the

December

balance of the carrying value of goodwill based on a single reporting unit annually. We perform an assessment of qualitative factors to determine if it is “more likely than

not”

that the fair value of our reporting unit is less than its carrying value as a basis for determining whether it is necessary to perform the

two

-step goodwill impairment test. The “more likely than

not”

threshold is defined as having a likelihood of more than

percent. If required, the next step of the goodwill impairment test is to determine the fair value of the reporting unit. The implied fair value of goodwill is determined on the same basis as the amount of goodwill recognized in connection with a business combination. Specifically, the fair value of a reporting unit is allocated to all of the assets and liabilities (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination as of the date of the impairment review and as if the fair value of the reporting unit was the price paid to acquire the reporting unit. The excess of the fair value of a reporting unit over the amounts assigned to its assets and liabilities is the implied fair value of goodwill. If the carrying amount of the reporting unit goodwill exceeds the implied fair value of that goodwill, an impairment loss shall be recognized in an amount equal to that excess. We have determined that

goodwill impairment charges were required for the years ended

December

31,

2019,

2018

2017.

Other Intangible Assets

Other intangible assets consist primarily of patents, trademarks, technology licenses, and customer relationships acquired in connection with business acquisitions and asset acquisitions and are amortized over their estimated useful lives, ranging from

years.

Stock-based Compensation

We recognize, as expense, the estimated fair value of stock options to employees which is determined using the Black-Scholes option pricing model. Share-based compensation charges are recorded across the consolidated statement of operations based upon the grantee’s primary function. We have elected to recognize the compensation cost of all share-based awards on a straight-line basis over the vesting period of the award. In periods that we grant stock options, fair value assumptions are based on volatility, interest, dividend yield, and expected term over which the stock options will be outstanding. The computation of expected volatility is based on the historical volatility of the company’s stock. The interest rate for periods within the contractual life of the award is based on the U.S. Treasury risk-free interest rate in effect at the time of grant. Historical data on exercise patterns is the basis for estimating the expected life of an option. The expected annual dividend rate was calculated by dividing our annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date.

We also issue restricted stock units (RSUs) as an additional form of equity compensation to our employees, officers, and directors, pursuant to our stockholder-approved

2006

Plan. RSUs entitle the grantee to an issuance of stock at

cost and generally vest over a period of time determined by our Board of Directors at the time of grant based upon the continued service to the company. The fair market value of the award is determined based on the number of RSUs granted and the market value of our common stock on the grant date and is amortized to expense over the period of vesting. Unvested RSUs are forfeited and canceled as of the date that employment or service to the company terminates. RSUs are settled in shares of our common stock upon vesting. We typically repurchase common stock upon our employees’ vesting in RSUs in order to cover any minimum tax withholding liability as a result of the RSUs having vested.

Commitments and Contingencies

In the normal course of business, we are subject to proceedings, lawsuits, and other claims and assessments for matters related to, among other things, patent infringement, business acquisitions, employment, commercial matters and product recalls. We assess the likelihood of any adverse judgments or outcomes to these matters as well as potential ranges of probable losses. A determination of the amount of reserves required, if any, for these contingencies is made after careful analysis of each individual issue. The required reserves

may

change in the future due to new developments in each matter or changes in approach such as a change in settlement strategy in dealing with these matters. We record charges for the losses we anticipate incurring in connection with litigation and claims against us when we conclude a loss is probable and we can reasonably estimate these losses. During the years ended

December

31,

2019,

2018

and

2017,

we were

not

subject to any material litigation or claims and assessments.

Income Taxes

We account for income taxes under the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred taxes are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The provision for income taxes includes taxes currently payable and deferred taxes resulting from the tax effects of temporary differences between the financial statement and tax bases of assets and liabilities. We maintain valuation allowances where it is more likely than

not

that all or a portion of a deferred tax asset will

not

be realized. Changes in the valuation allowances are included in our tax provision in the period of change. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carry-back and carry-forward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset.

We recognize, measure, present and disclose in our financial statements, uncertain tax positions that we have taken or expect to take on a tax return. We recognize in our financial statements the impact of tax positions that meet a “more likely than

not”

threshold, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than

fifty

percent likelihood of being realized upon ultimate settlement.

Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.

Comprehensive Income

Comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other than reported net income, comprehensive income includes foreign currency translation adjustments, which are disclosed in the accompanying consolidated statements of comprehensive income. There were

reclassifications out of comprehensive income for the years ended

December

31,

2019,

2018

2017.

Accumulated other comprehensive loss consisted primarily of foreign currency translation adjustment losses of

$4.0

million and

$3.9

million as of

December

31,

2019

and

2018,

respectively.

Restructuring

We record restructuring charges incurred in connection with consolidation or relocation of operations, exited business lines, reductions in force, or distributor terminations. These restructuring charges, which reflect our commitment to a termination or exit plan that will begin within

twelve

months, are based on estimates of the expected costs associated with site closure, legal matters, contract terminations, severance payments, or other costs directly related to the restructuring. If the actual cost incurred exceeds the estimated cost, an additional charge to earnings will result. If the actual cost is less than the estimated cost, a credit to earnings will be recognized.

Earnings per Share

We compute basic earnings per share by dividing net income available for common stockholders by the weighted average number of shares outstanding during the year. Except where the result would be anti-dilutive to net income per share, diluted earnings per share has been computed using the treasury stock method and reflects the potential vesting of restricted common stock and the potential exercise of stock options, as well as their related income tax effects.

The computation of basic and diluted net income per share is as follows:

	Year ended December 31,
	2019		2018		2017
	(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	17,934	$	22,943	$	17,177

Weighted average shares outstanding		19,813		19,426		18,961

Basic earnings per share	$	0.91	$	1.18	$	0.91

Diluted:
Net income available for common stockholders	$	17,934	$	22,943	$	17,177

Weighted-average shares outstanding		19,813		19,426		18,961
Common stock equivalents, if dilutive		513		816		1,072


Shares used in computing diluted earnings per common share		20,326		20,242		20,033

Diluted earnings per share	$	0.88	$	1.13	$	0.86

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		468		230		6

Recent Accounting Pronouncements

January 1, 2019

we adopted the provisions of ASU

No.

2016

02,

Leases (Topic

842

subsequently amended by ASU

2018

11,

Leases (Topic

842

): Targeted Improvements

. Under the new guidance, we are required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. As allowed by the standard, we elected to use the transition option

not

to apply the new lease standard to comparative periods but instead to recognize a cumulative-effect adjustment to retained earnings as of the date of adoption,

January 1, 2019.

Upon adoption of this standard, we recognized lease liabilities of

$7.0

million and right-of-use assets in the amount of

$6.5

million (net of the reversal of a previously recorded deferred rent liability of

$0.5

million). There was

cumulative-effect adjustment to retained earnings required. Additional disclosures required under the new standard are included in Note

to these financial statements.

June 2016,

the FASB issued ASU

2016

Financial Instruments – Credit Losses (Topic

326

), which requires a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions and reasonable, supportable forecasts that affect the collectability of the reported amount, and requires judgment in determining relevant information and estimation methods. The new standard is effective for us beginning

January

2020.

The adoption of this standard is

not

expected to have a material impact on our financial statements, as the only financial assets we have that are affected by the standard are trade receivables for which we have historically employed a collectability estimation technique.

August 2018,

the FASB issued ASU

2018

Fair Value Measurement (Topic

820

), which modifies the disclosure requirements for fair value measurements. The new standard is effective for us beginning

January

2020,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

January 2017,

the FASB issued ASU

2017

Intangibles – Goodwill and Other (Topic

350

), which, among other provisions, eliminates “step

2”

from the goodwill impairment test. The annual, or interim, goodwill impairment test will be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should

not

exceed the total amount of goodwill allocated to that reporting unit. The new standard is effective for us beginning

January

2020,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

December 2019,

the FASB issued ASU

2019

Income Taxes (Topic

740

), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic

740

as well as clarifying and amending other areas of existing GAAP under Topic

740.

The new standard is effective for us beginning

January

2021,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

Note 2 - Acquisitions and Divestitures

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Business Combination Disclosure [Text Block]

Acquisitions and Divestitures

Acquisitions are accounted for using the acquisition method and the acquired businesses’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. In each case for the acquisitions disclosed below, pro forma information assuming the acquisition had occurred at the beginning of the earliest period presented is

not

included as the impact is immaterial.

Our acquisitions have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of synergies that will be realized by combining businesses. These synergies include the use of our existing sales channel to expand sales of the acquired businesses’ products, consolidation of manufacturing facilities, and the leveraging of our existing administrative infrastructure.

The fair market valuations associated with these transactions fall within Level

(see Note

) of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long range strategic plans and other estimates.

CardioCel and VascuCel Biologic Patches

October 11, 2019 (

the Closing Date), we entered into an Asset Purchase Agreement (APA) to acquire the biologic patch business assets and a related technology license from Admedus Ltd and various of its subsidiaries (Admedus). The biologic patch business consists of the CardioCel and VascuCel product lines, which are manufactured in a manner intended to reduce the risk of calcification. The products are sold worldwide. On the same date, the parties entered into a Transition Services Agreement (TSA) under which Admedus will manufacture and supply LeMaitre with inventory for a period of up to

three

years, unless extended in writing by both parties. Revenues from the acquisition date through

December 31, 2019

were

$1.4

million.

Under the APA we agreed to pay Admedus a total of up to

$15.3

million for the purchase of substantially all of its biologic patch business assets, other than specifically identified Excluded Assets, plus

$8.0

million for the technology licenses. The acquired assets (in combination with the license) included inventory, intellectual property, permits and approvals, data and records, and customer and supplier information, as well as a small amount of machinery and equipment. At closing,

$14.2

million of the purchase price was paid to Admedus. Shortly thereafter another

$0.3

million was paid in connection with delivery of audited financial statements of the acquired business to LeMaitre. Additional consideration

may

be payable as follows:

●

$0.7

million (the First Holdback) within

days following the

first

anniversary of the Closing Date;

●

$0.7

million (the Second Holdback) within

days following the

third

anniversary of the Closing Date;

●

$2.0

million (the Third Holdback) within

days following LMAT’s receipt of a CE mark on all acquired products;

●

$2.5

million if revenues in the

first

-month period following the Closing Date exceed

$20

million, OR,

$1.2

million if revenues in the

first

-month period following the Closing Date exceed

$15

million;

●

$2.5

million if revenues in the

second

-month period following the Closing Date exceed

$30

million, OR,

$1.2

million if revenues in the

first

-month period following the Closing Date exceed

$22.5

million; and

●

$0.5

million if by the

first

anniversary of the Closing Date Admedus extends the shelf life of the products from

months to at least

months

The following table summarizes the preliminary purchase price allocation:

	Allocated
	Fair Value
	(in thousands)
Inventory and other	$	1,343
Intangible assets		8,725
Goodwill		7,344

Purchase price	$	17,412

The goodwill results from expected synergies of combining the acquired products and customer information to our existing operations, and is deductible for tax purposes over

years.

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:

			Weighted
	Allocated		Average
	Fair Value		Useful Life (years)
	(in thousands)
Customer relationships	$	5,562	12.0
Intellectual property		2,335	8.0
Non-compete agreement		361	5.0
Tradenames		467	8.0

Total intangible assets	$	8,725

The weighted-average amortization period of the acquired intangible assets was

10.4

years.

Tru-Incise Valve Cutter

July 12, 2019,

we entered into an agreement with UreSil, LLC, an Illinois limited liability company, to purchase the remaining assets of their Tru-Incise valve cutter business, including distribution rights in the United States. We also entered into a transition services agreement under which UreSil, LLC will continue to manufacture the acquired products for us for a specified time, until we transition the full manufacturing process to our Burlington, Massachusetts facilities. Revenues from the acquisition date through

December 31, 2019

were

$0.8

million.

The purchase price for the acquired assets, which included inventory, machinery and equipment, intellectual property, and customer and supplier information, was

$8.0

million. Of this amount,

$6.8

million was paid at closing, with

three

follow-on payments

$0.4

million each due on the first,

second

and

third

anniversaries of the closing date. The deferred amounts totaling

$1.2

million were recorded at an acquisition-date fair value of

$1.1

million using a discount rate of

4.19%

to reflect the time value of money between the acquisition date and the payment due dates. There are

contingencies associated with these holdback payments, although they

may

be reduced for certain post-closing claims.

The following table summarizes the preliminary purchase price allocation:

	Allocated
	Fair Value
	(in thousands)
Inventory	$	276
Equipmentand supplies		70
Intangible assets		4,844
Goodwill		2,748

Purchase price	$	7,938

The goodwill results from expected synergies of combining the acquired products and customer information to our existing operations, and is deductible for tax purposes over

years.

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:

			Weighted
	Allocated		Average
	Fair Value		Useful Life (years)
	(in thousands)
Customer relationships	$	3,945	13.0
Intellectual property		563	7.0
Non-compete agreement		233	5.0
Tradenames		103	7.0

Total intangible assets	$	4,844

The weighted-average amortization period of the acquired intangible assets was

11.8

years.

Cardial

October 22, 2018,

through a newly created subsidiary LeMaitre Cardial SAS, we entered into an agreement to acquire the business assets of Cardial, a company located in Saint-Etienne, France and formerly owned by Becton, Dickinson and Company. The Cardial business consists of the manufacturing of polyester vascular grafts, valvulotomes and surgical glue. On the same date, the parties entered into a separate agreement notarial deed under which LeMaitre Cardial SAS purchased the building and land previously owned by Cardial.

The purchase price for the acquired assets, including the land and building, inventory, machinery and equipment, intellectual property, permits and approvals, data and records, and customer and supplier information, was

€2.0

million (

$2.3

million). At closing,

€1.1

million (

$1.3

million) was paid in cash, and

€0.5

million (

$0.5

million) of liabilities were assumed by LeMaitre Cardial SAS. Another

€0.4

million (

$0.4

million) is due in

two

installments, half to be paid

twelve

months after the closing date, and half

eighteen

months after the closing date. There are

contingencies associated with these holdback payments, although they

may

be reduced depending upon the final results of a reconciliation of the value of inventory transferred, as outlined in the agreement.

The following table summarizes the purchase price allocation:

	Allocated
	Fair Value
	(in thousands)
Inventory	€	2,419
Land and building		750
Equipment and supplies		94
Intangible assets		623
Bargain purchase gain		(1,946	)

Purchase price	€	1,940

The bargain purchase gain was recorded to reflect the excess of the net assets acquired over the purchase price. We recorded deferred taxes on this gain of

€0.5

million (

$0.6

million), resulting in a net gain of

€1.4

million (

$1.6

million).

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:

			Weighted
	Allocated		Average
	Fair Value		Useful Life (years)
	(in thousands)
Customer relationships	€	250	16.0
Intellectual property		237	5.0
Non-compete agreement		46	5.0
Tradenames		90	5.0

Total intangible assets	€	623

The weighted-average amortization period of the acquired intangible assets was

9.4

years.

Applied Medical

September 20, 2018,

we entered into an agreement to acquire the assets of the embolectomy catheter business of Applied Medical Resources Corporation (Applied). The clot management business consists of several embolectomy and thrombectomy catheter product lines which are sold worldwide (approximately

60%

in the U.S. and

40%

outside the U.S.). On the same date, we entered into a transition services agreement under which Applied will manufacture and supply us with inventory for a period of

twelve

months, unless extended in writing by both parties.

The purchase price for the acquired assets, which included inventory, machinery and equipment, intellectual property, permits and approvals, data and records, and customer and supplier information, was

$14.2

million. Of this amount,

$11

million was paid at closing, another

million was paid

months following the closing date, and the final

$1.2

million is due

months following the closing date. The deferred amounts totaling

$3.2

million were recorded at an acquisition-date fair value of

$3.043

million using a discount rate of

3.75%

to reflect the time value of money between the acquisition date and the payment due dates.

The following table summarizes the purchase price allocation. The purchase accounting is complete:

	Allocated
	Fair Value
	(in thousands)
Inventory	$	739
Equipment and supplies		416
Intangible assets		6,527
Goodwill		6,361

Purchase price	$	14,043

The goodwill results from expected synergies of combining the acquired products and customer information to our existing operations, and is deductible for tax purposes over

years.

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:

			Weighted
	Allocated		Average
	Fair Value		Useful Life (years)
	(in thousands)
Customer relationships	$	4,475	16.0
Intellectual property		1,316	7.0
Non-compete agreement		530	5.0
Tradenames		206	7.0

Total intangible assets	$	6,527

The weighted-average amortization period of the acquired intangible assets was

13.0

years.

Reddick Divestiture

April

2018,

we entered into an asset purchase agreement with Specialty Surgical Instrumentation, Inc. to sell the inventory, intellectual property and other assets associated exclusively with our Reddick cholangiogram catheter and Reddick-Saye screw product lines for

$7.4

million. Concurrent with this divestiture we entered into a transition services agreement under which we will continue to manufacture and supply these products to the buyer for a period of up to

two

years unless extended by both parties, as well as a balloon supply agreement under which we will supply balloons, a component of the cholangiogram catheters, to the buyer for a period of up to

six

years unless extended by both parties. We recorded a gain in connection with these agreements of

$5.9

million. The following table summarizes the allocation of consideration received:

	Allocated
	Fair Value
	(in thousands)
Inventory	$	308
Deferred revenue - transition services agreement		1,081
Goodwill		135
Gain on divestiture		5,876

Consideration received	$	7,400

Under the terms of the transition services agreement, we agreed to manufacture the Reddick products for the buyer at prices at or in some cases below our cost. We allocated a portion of the consideration received to this agreement to reflect it at fair value and recorded it as deferred revenue. As the products were sold to the buyer, we amortized a portion of the deferred revenue to adjust the gross margin on the sale to fair value on a specific identification basis. Additionally, as the Reddick product lines that were divested constituted a business, we allocated a portion of our goodwill to this divestiture based on the fair value of the business sold in relation to the fair value of the business that will be retained.

Note 3 - Inventories and Other Deferred Costs

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Inventory and Other Deferred Costs Disclosure [Text Block]

Inventory and Other Deferred Costs

Inventory and other deferred costs consists of the following:

	December 31, 2019		December 31, 2018
	(in thousands)
Raw materials	$	5,359	$	4,085
Work-in-process		6,238		5,095
Finished products		23,032		16,391
Other deferred costs		4,898		1,817

Total inventory and other deferred costs	$	39,527	$	27,388

We had inventory on consignment at customer sites of

$1.9

million and

$1.7

million as of

December

31,

2019

and

2018,

respectively.

In connection with our RestoreFlow allograft business, other deferred costs include costs incurred for the preservation of human vascular tissues available for shipment, tissues currently in active processing, and tissues held in quarantine pending release to implantable status. By federal law, human tissues cannot be bought or sold. Therefore, the tissues we preserve are

not

held as inventory, and the costs we incur to procure and process vascular tissues are instead accumulated and deferred. These costs include fixed and variable overhead costs associated with the cryopreservation process, including primarily direct labor costs, tissue recovery fees, inbound freight charges, indirect materials and facilities costs. General and administrative expenses and selling expenses associated with the provision of these services are expensed as incurred.

Note 4 - Property and Equipment

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

Property and Equipment

Property and equipment consists of the following:

	As of December 31,
	2019			2018
	(in thousands)
Computers and equipment	$	4,623		$	4,077
Machinery and equipment		16,245			13,718
Building and leasehold improvements		11,758			11,651

Gross property and equipment		32,626			29,446
Less accumulated depreciation		(17,772	)		(15,344	)

Property and equipment, net	$	14,854		$	14,102

During the years ended

December 31, 2019,

2018

and

2017

we wrote off fully depreciated assets with gross values of

$0.5

million,

$1.0

million and

$0.2

million, respectively.

Depreciation expense is as follows:

	Year ended December 31,
	2019		2018		2017
			(in thousands)

Depreciation expense	$	2,979	$	2,564	$	2,266

Note 5 - Goodwill and Other Intangibles

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Goodwill and Intangible Assets Disclosure [Text Block]

Goodwill and Other Intangibles

Goodwill consists of the following:

	As of December 31,
	2019			2018

Balance at beginning of year	$	29,868		$	23,844
Additions for acquisitions		10,092			6,361
Divestiture adjustment		-			(135	)
Effects of currency exchange		(9	)		(202	)

Balance at end of year	$	39,951		$	29,868

Other intangibles consist of the following:

	December 31, 2019						December 31, 2018
	Gross				Net		Gross				Net
	Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
	Value		Amortization		Value		Value		Amortization		Value
	(in thousands)
Product technology and intellectual property	$	13,502	$	5,722	$	7,780	$	11,728	$	5,726	$	6,002
Trademarks, tradenames and licenses		1,807		702		1,105		2,246		1,561		685
Customer relationships		18,215		3,364		14,851		10,065		3,806		6,259
Other intangible assets		1,725		568		1,157		2,145		1,399		746

Total identifiable intangible assets	$	35,249	$	10,356	$	24,893	$	26,184	$	12,492	$	13,692

These assets are being amortized over useful lives ranging from

years. The weighted-average amortization period for these intangibles as of

December

31,

2019,

10.1

years. Amortization expense is included in general and administrative expense and is as follows:

	Year ended December 31,
	2019		2018		2017
			(in thousands)

Amortization expense	$	2,437	$	1,760	$	1,790

During the year ended

December 31, 2019

we wrote off fully amortized intangible assets with a gross values of

$4.5

million. Estimated amortization expense for each of the next

five

fiscal years, based upon the intangible assets at

December

31,

2019,

is as follows:

	Year ended December 31,
	2020		2021		2022		2023		2024
	(in thousands)

Amortization expense	$	3,224	$	2,956	$	2,751	$	2,677	$	2,477

Note 6 - Accrued Expenses and Other Long-term Liabilities

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]

Accrued Expenses and Other Long-term Liabilities

Accrued expenses consist of the following:

	December 31, 2019		December 31, 2018
	(in thousands)
Compensation and related taxes	$	8,550	$	7,973
Income and other taxes		1,003		2,927
Professional fees		40		43
Deferred revenue		-		552
Other		4,421		4,352

Total	$	14,014	$	15,847

As discussed in Note

above, deferred revenue relates to our divestiture of the Reddick product line and an associated transition services agreement that we entered into contemporaneously with the divestiture, under which we agreed to manufacture and sell product to the buyer at prices at or below our cost. We allocated a portion of the consideration received from the divestiture to this transition services agreement to reflect it at fair value and recorded it as deferred revenue. As the products were sold to the buyer, we amortized a portion of the deferred revenue to adjust the gross margin on the sale to fair value on a specific identification basis. This arrangement is now complete. The following table summarizes the changes in the deferred revenue balance during the arrangement:

	As of December 31,
	2019			2018

Beginning contract liability balance	$	552		$	-
Deferred revenue recorded		-			1,081
Revenue recognized upon satisfaction of performace obligations in the period		(552	)		(529	)

Ending balance	$	-		$	552

Other long-term liabilities consist of the following:

	December 31, 2019		December 31, 2018
	(in thousands)
Acquisition-related liabilities	$	3,268	$	1,326
Deferred rent		-		530
Income taxes		781		559
Other		166		196

Total	$	4,215	$	2,611

Note 7 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

Commitments and Contingencies

Leases

We conduct the majority of our operations in leased facilities, all of which are accounted for as operating leases, as they do

not

meet the criteria for finance leases. Our principal worldwide executive, distribution, and manufacturing operations are located at

three

adjacent

27,098

square foot,

27,289

square foot and

15,642

square foot leased facilities, as well as a

fourth

nearby

12,878

square foot leased facility, in Burlington, Massachusetts. In

October 2019

we leased an additional

26,447

square foot building in the same area from the same landlord from whom we lease the other

four

buildings, and also extended the lease terms on the other

four

buildings. All

five

Burlington leases now expire in

December 2030.

October 2019

we also leased a

2,258

square foot facility in Hereford, England to house our United Kingdom sales and distribution business. In addition, our international operations are headquartered at a

16,470

square foot leased facility located in Sulzbach, Germany, including approximately

3,630

square feet added in

2019,

under a lease which expires in

August 2023.

This lease contains

two five

-year renewal options. We also have smaller long-term leased sales, marketing and other facilities located in Arizona, Japan, Canada, Australia, Singapore and China, and short-term leases in Italy, Spain and Illinois. Our lease in Canada contains a

five

-year renewal option exercisable in

February 2023.

Our leases in Germany and Australia are subject to periodic rent increases based on increases in the consumer price index as measured each

September

and

May,

respectively, with such increases applicable to the subsequent

twelve

months of lease payments.

None

of our noncancelable lease payments include non-lease components such as maintenance contracts; we generally reimburse the landlord for direct operating costs associated with the leased space. We have

subleases, and there are

residual value guarantees associated with, or restrictive covenants imposed by, any of our leases. There were

assets held under capital leases at

December 31, 2019.

We also lease automobiles under operating leases in the U.S. as well as certain of our international subsidiaries. The terms of these leases are generally

three

years, with older vehicles replaced by newer vehicles from time to time.

As discussed above under Recent Accounting Pronouncements, on

January 1, 2019

we adopted the provisions of ASU

No.

2016

02,

Leases (Topic

842

subsequently amended by ASU

2018

11,

Leases (Topic

842

): Targeted Improvements

Our most significant judgment involved in determining the amounts to initially record as lease liabilities and right-of-use assets was the selection of a discount rate; because we have

debt we have

incremental borrowing rate to reference. We therefore estimated an incremental borrowing rate using quotes from potential lenders as the primary inputs, augmented by other available information. The resulting rate selected was

5.25%.

We determined that it was appropriate to apply this single rate to our portfolio of leases worldwide, as the lease terms and conditions are substantially similar, and because we believe our subsidiaries would be unable to obtain borrowings on their own without a commitment of parent company support.

Additional information with respect to our leases is as follows:

	Year ended
	December 31,
	2019
	(in thousands)

Lease cost
Operating lease cost	$	1,756
Short-term lease cost		291
Total lease cost	$	2,047

Other information
Cash paid for amounts included in the measurement of operating lease liabilities	$	1,858

Right-of-use assets obtained in exchange for new operating lease liabilities	$	10,571


Weighted average remaining lease term - operating leases (years)		8.3

Weighted average discount rate - operating leases		5.25	%

December 31, 2019,

the minimum noncancelable operating lease rental commitments with initial or remaining terms of more than

one

year are as follows:

Year ending December 31,
2020	$	2,419
2021		2,351
2022		1,942
2023		1,686
2024		1,573
Thereafter		10,301
Adjustment to net present value as of December 31, 2019		(4,560	)

Minimum noncancelable lease liability	$	15,712

Purchase Commitments

As part of our normal course of business, we have commitments to purchase

$1.5

million of inventory through

2019.

The purchase commitments for inventory are to be used in operations over the normal course of business and do

not

represent excess commitments or loss contracts.

Note 8 - Income Taxes

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Income Tax Disclosure [Text Block]

Income Taxes

Income (loss) before income taxes is as follows:

	Year ended December 31,
	2019		2018		2017
	(in thousands)

United States	$	17,989	$	22,256	$	17,778
Foreign		3,690		6,188		3,328

Total	$	21,679	$	28,444	$	21,106

Certain of our foreign subsidiaries are included in the U.S. tax return as branches but are included as foreign for purposes of the table above.

The provision (benefit) for income taxes is as follows:

	Year ended December 31,
	2019		2018			2017
			(in thousands)
Current:
Federal	$	1,501	$	4,262		$	2,451
State		304		673			292
Foreign		1,116		2,718			886

		2,921		7,653			3,629
Deferred:
Federal		538		(1,512	)		(268	)
State		144		(145	)		390
Foreign		142		(495	)		178

		824		(2,152	)		300

Provision for income taxes	$	3,745	$	5,501		$	3,929

We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of

December

31,

2019,

the gross amount of unrecognized tax benefits exclusive of interest and penalties was

$0.8

million, which

may

increase within the

twelve

months ending

December

31,

2020.

We remain subject to examination until the statute of limitations expires for each respective tax jurisdiction. The statute of limitations will be open with respect to these tax positions through

2027.

A reconciliation of beginning and ending amount of our unrecognized tax benefits is as follows:

	2019		2018		2017
	(in thousands)
Unrecognized tax benefits at the beginning of year	$	711	$	525	$	390
Additions for tax positions of current year		74		73		83
Additions for tax positions of prior years		63		113		57
Reductions for settlements with taxing authorities.		-		-		-
Reductions for lapses of the applicable statutes of limitations		-		-		(5	)
Unrecognized tax benefits at the end of the year	$	848	$	711	$	525

Deferred taxes are attributable to the following temporary differences:

	As of December 31,
	2019			2018
	(in thousands)
Deferred tax assets:
Inventory	$	840		$	976
Net operating loss carryforwards		1,289			1,421
Tax credit carryforwards		944			828
Capital loss carryforwards		277			279
Reserves and accruals		787			802
Operating lease liabilities		3,343			-
Intangible assets		2,764			2,737
Stock options		342			373
Other		20			91

Total deferred tax assets		10,606			7,507

Deferred tax liabilities:
Property and equipment		(1,520	)		(1,416	)
Goodwill		(3,459	)		(3,023	)
Operating lease right-of-use assets		(3,224	)		-
Foreign branch deferred offset		(923	)		(1,032	)
Other		(187	)		(50	)

Total deferred tax liabilities		(9,313	)		(5,521	)

Net deferred tax assets before valuation allowance		1,293			1,986

Valuation allowance		(1,388	)		(1,255	)

Net deferred tax liabiltity	$	(95	)	$	731

Deferred tax classification
Long-term deferred tax asset	$	1,084		$	1,215
Long-term deferred tax liability		(1,179	)		(484	)

Net long-term deferred tax liability	$	(95	)	$	731

2017,

we increased our valuation by a net

$0.2

million mainly attributable to Massachusetts credit carryforwards. In

2018,

we decreased our valuation allowance by a net

$0.7

million mainly attributable to Australian net operating loss and capital loss carry forwards that are now expected to be realized. In

2019,

we increased our valuation allowance by

$0.1

million mainly attributable to Australian net operating loss carry forwards and Massachusetts credit carryforwards.

As of

December 31, 2019,

we have provided a valuation allowance of

$1.4

million for deferred tax assets primarily related to Australian net operating loss and capital loss carry forwards and Massachusetts tax credit carry forwards that are

not

expected to be realized. The valuation allowance against our deferred tax assets

may

require adjustment in the future based on changes in the mix of temporary differences, changes in tax laws, and operating performance.

Realization of our deferred tax assets is dependent on our generating sufficient taxable income in future periods. Although we believe it is more likely than

not

that future taxable income will be sufficient to allow us to recover substantially all of the value of our deferred tax assets remaining after we apply the valuation allowances, realization is

not

assured and future events could cause us to change our judgment. In the event that actual results differ from our estimates, or we adjust these estimates in the future periods, further adjustments to our valuation allowance

may

be recorded, which could materially impact our financial position and net income (loss) in the period of the adjustment.

As of

December

31,

2019,

we have net operating loss carryforwards in Australia of

$1.2

million that do

not

expire, in France of

$2.5

million that do

not

expire, in Spain of

$0.9

million that do

not

expire, and in Norway of

$0.1

million that do

not

expire. We have a capital loss carryforward in Australia of

$0.9

million that does

not

expire. We also have state tax credit carryforwards of approximately

$1.5

million that are available to reduce future tax liabilities, which begin to expire in

2021,

or can be carried forward indefinitely.

December 2018,

we reevaluated our international operations and as a result, are

longer indefinitely reinvested with respect to undistributed earnings from our German and Australian subsidiaries. There was

material deferred tax expense recorded for foreign and state tax costs associated with the future remittance of these undistributed earnings. We remain permanently reinvested with respect to undistributed earnings from our other foreign subsidiaries. It is

not

practicable to estimate the amount of deferred tax liability, if any, with respect to these permanently reinvested undistributed earnings.

A reconciliation of the federal statutory rate to our effective tax rate is as follows:

	2019			2018			2017

Federal statutory rate		21.0	%		21.0	%		35.0	%
State tax, net of federal benefit		1.9	%		1.4	%		1.7	%
Effect of foreign taxes		2.1	%		3.8	%		(0.6%	)
Federal tax on foreign income		0.8	%		1.4	%		1.7	%
Valuation allowance		0.6	%		(3.2%	)		0.1	%
Foreign deferred tax liability offset		(0.4%	)		(0.3%	)		(0.2%	)
Manufacturing deduction		0.0	%		0.0	%		(1.5%	)
Research & development tax credits		(1.2%	)		(0.7%	)		(0.6%	)
Stock options		(8.8%	)		(3.3%	)		(15.8%	)
Uncertain tax positions		1.0	%		0.8	%		0.6	%
Other permanent differences		0.5	%		(0.7%	)		1.0	%
Change in tax laws		0.0	%		0.0	%		2.9	%
Deferred tax remeasurement		0.0	%		0.0	%		(5.0%	)
Other		(0.2%	)		(0.9%	)		(0.7%	)

Effective tax rate		17.3	%		19.3	%		18.6	%

August 2018,

the German tax authority commenced an audit of our German subsidiary for the tax years

2013

through

2016.

We expect to conclude this audit in early

2020

and pay an immaterial amount of additional German tax. We are

not

currently under audit in any other tax jurisdictions.

As of

December

31,

2019,

a summary of the tax years that remain subject to examination in our most significant tax jurisdictions are:

United States	2016 and forward
Foreign	2012 and forward

Note 9 - Stockholders' Equity

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

Stockholders’ Equity

Authorized Shares

Our certificate of incorporation, as amended and restated from time to time, authorizes the issuance of up to

37,000,000

shares of common stock and up to

3,000,000

shares of undesignated preferred stock.

Under the terms of our certificate of incorporation, our board of directors is authorized to issue shares of the preferred stock in

one

or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. Currently, we have

shares of preferred stock outstanding.

Stock Award Plans

May 2006

we approved a

2006

Stock Option and Incentive Plan (as subsequently amended, the

2006

Plan), which became effective upon our initial public offering. The

2006

Plan allows for the granting of an aggregate

5,500,000

shares of incentive stock options, non-qualified stock options, stock appreciation rights, RSUs, unrestricted stock awards, and deferred stock awards to our officers, employees, directors, and consultants. Incentive stock options are required to be issued at

not

less than fair market value at the date of the grant and generally vest over

four

five

years. The term of the options is determined by our Board of Directors but in

event will exceed

ten

years from date of grant. In connection with the adoption of the

2006

Plan,

further option grants were permitted under any previous stock option plans and any expirations, cancellations, or terminations under the previous plans are available for issuance under the

2006

Plan. We

may

satisfy awards upon exercise of stock options or RSUs with either newly issued shares or treasury shares. The total number of shares currently authorized for the

2006

Plan is

7,118,003

shares, of which

1,089,749

remain available for grant as of

December

31,

2019.

We have computed the fair value of employee stock options granted each year using the following weighted average assumptions:

	2019			2018			2017
Dividend yield		0.96	%		1.20	%		0.70	%
Volatility		42.8	%		41.3	%		39.1	%
Risk-free interest rate		1.7	%		2.7	%		2.2	%
Weighted average expected option term (in years)		4.7			4.8			4.6
Weighted average fair value per share of options granted	$	12.51		$	8.28		$	10.37

A summary of option activity as of

December

31,

2019

and the year then ended is presented below:

				Weighted		Weighted Average	Aggregate
	Number			Average		Remaining	Intrinsic
	of Shares			Exercise Price		Contractual Term	Value
						(in years)
Balance outstanding at December 31, 2018 (1)		1,462,575		$	16.41	4.54	$	12,214,422

Granted		195,379		$	35.53
Exercised (2)		(509,693	)	$	9.53		$	11,488,292
Canceled / Expired		(101,167	)	$	17.90
Balance outstanding at December 31, 2019 (3)		1,047,094		$	23.19	4.31	$	13,366,595

Vested and exercisable at December 31, 2019 (4)		309,501		$	19.64	3.50	$	5,046,733
Expected to vest at December 31, 2019		737,593		$	24.68	4.65
Total		1,047,094

(

)

The aggregate intrinsic value represents the difference between the exercise price and

$23.64,

the closing price of our stock on

December

31,

2018,

for all in-the-money options outstanding.

(

)

The aggregate intrinsic value of shares exercised represents the difference between the exercise price and the closing price of our stock on the date of exercise.

(

)

The aggregate intrinsic value represents the difference between the exercise price and

$35.95,

the closing price of our stock on

December

31,

2019,

for all in-the-money options outstanding.

(

)

The aggregate intrinsic value represents the difference between the exercise price and

$35.95,

the closing price of our stock on

December

31,

2019,

for all in-the-money options vested and exercisable as of that date.

Restricted Stock Units

A summary of our RSU activity is as follows:

				Weighted
				Average
				Grant Date
	Shares			Fair Value

Balance outstanding at December 31, 2018		217,895		$	21.21

Granted		56,567		$	35.41
Vested (1)		(61,058	)	$	18.46
Canceled		(24,723	)	$	22.19

Balance outstanding at December 31, 2019		188,681		$	26.14

(

)

The number of RSUs vested includes the shares that we withheld on behalf of employees to satisfy minimum statutory tax withholding requirements.

The fair values of the RSUs that vested during

2019,

2018,

and

2017

were

$2.1

million,

$1.9

million, and

$1.9

million, respectively.

We repurchase shares of our common stock in order to cover any minimum tax withholding liability associated with RSU vestings. A summary of our repurchases is as follows:

	2019		2018

Shares of common stock repurchased		20,524		21,410
Average per share repurchase price	$	33.28	$	34.62
Aggregage purchase price (in thousands)	$	683	$	741

Stock-based Compensation

The components of stock-based compensation expense included in the consolidated statements of operations are as follows:

	2019		2018		2017
	(in thousands)
Stock option awards	$	1,580	$	1,457	$	1,612
Restricted stock units		1,062		892		644

Total stock-based compensation	$	2,642	$	2,349	$	2,256

Stock-based compensation is included in our statements of operations as follows:

	2019		2018		2017
	(in thousands)
Cost of sales	$	310	$	272	$	188
Sales and marketing		544		529		403
General and administrative		1,509		1,293		1,484
Research and development		279		255		181

Total stock-based compensation	$	2,642	$	2,349	$	2,256

We expect to record the unamortized portion of share-based compensation expense of

$10.4

million for existing stock options and RSUs outstanding at

December

31,

2019,

over a weighted-average period of

3.8

years.

Stock Repurchase Plan

February 14, 2019,

our Board of Directors authorized the repurchase of up to

$10.0

million of the Company’s common stock through transactions on the open market, in privately negotiated purchases or otherwise until

February 14, 2020.

February 13, 2020

the Board extended the term of the repurchase program to

February 14, 2021.

The repurchase program

may

be suspended or discontinued at any time. To date we have

not

made any repurchases under this program.

Dividends

February 2011,

our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:

Record Date	Payment Date	Per Share Amount		Dividend Payment
				(in thousands)
Fiscal Year 2019
March 22, 2019	April 5, 2019	$	0.085	$	1,672
May 22, 2019	June 6, 2019	$	0.085	$	1,672
August 21, 2019	September 5, 2019	$	0.085	$	1,691
November 20, 2019	December 5, 2019	$	0.085	$	1,701


Fiscal Year 2018
March 22, 2018	April 5, 2018	$	0.070	$	1,351
May 22, 2018	June 7, 2018	$	0.070	$	1,353
August 22, 2018	September 6, 2018	$	0.070	$	1,369
November 20, 2018	December 6, 2018	$	0.070	$	1,372

February

13,

2020,

our Board of Directors approved a quarterly cash dividend on our common stock of

$0.095

per share payable on

March 19, 2020

to stockholders of record at the close of business on

March

2020

which will total approximately

$1.9

million.

Note 10 - Profit-sharing Plan	12 Months Ended
Note 10 - Profit-sharing Plan	Dec. 31, 2019
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	10. Profit-Sharing Plan We offer a 401 (k) profit-sharing plan (the Plan) covering eligible U.S. employees to make tax deferred contributions, a portion of which are matched by us. We may make discretionary profit sharing contributions to the Plan in an amount determined by our Board of Directors. Our contributions vest ratably over six years of employment and amounted to approximately $0.4 million, $0.3 million and $0.2 million for 2019, 2018 and 2017, respectively.

Note 11 - Segment and Enterprise-wide Disclosures

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

. Segment and Enterprise-wide Disclosures

The FASB establishes standards for reporting information regarding operating segments in financial statements. Operating segments are identified as components of an enterprise that engage in business activities for which separate, discrete financial information is available and is regularly reviewed by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. We view our operations and manage our business as

one

operating segment.

discrete operating information is prepared by us except for sales by product line and operations by legal entity for local reporting purposes.

Most of our revenues are generated in the United States, Germany, and other European countries, Canada, the United Kingdom and Japan, and substantially all of our assets are located in the United States, Australia and France. Net sales to unaffiliated customers by country were as follows:

	Year ended December 31,
	2019		2018		2017
	(in thousands)

United States	$	63,130	$	59,078	$	58,470
Germany		12,400		12,445		11,576
Other countries		41,702		34,045		30,821

Net sales	$	117,232	$	105,568	$	100,867

Total long-term assets by country, including property and equipment, net and right-of-use leased assets were as follows:

	As of December 31,
	2019		2018
	(in thousands)

United States	$	24,885	$	11,006
Australia		1,499		1,460
France		1,089		1,071
Germany		1,405		430
Other countries		1,184		135

Total long-term assets	$	30,062	$	14,102

Note 12 - Supplemental Cash Flow Information

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Cash Flow, Supplemental Disclosures [Text Block]

. Supplemental Cash Flow Information

Supplemental disclosures of cash flow information are as follows:

	Year ended December 31,
	2019		2018		2017
	(in thousands)
Cash paid for income taxes, net	$	4,817	$	5,521	$	3,146

Note 13 - Fair Value Measurements

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Fair Value Disclosures [Text Block]

. Fair Value Measurements

The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in

one

of the following

three

categories:

•

Level

— Quoted prices in active markets for identical assets or liabilities.

•

Level

— Observable inputs other than quoted prices included in Level

such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are

not

active; or other inputs that are observable or can be corroborated by observable market data.

•

Level

— Unobservable inputs that are supported by little or

market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

Level

assets being measured at fair value on a recurring basis as of

December

31,

2019

included our short-term investment mutual fund account.

We had

Level

assets being measured at fair value on a recurring basis as of

December

31,

2019.

As discussed in Notes

and

several of our acquisition-related assets and liabilities have been measured using Level

techniques. During

2019,

we recorded contingent liabilities associated with our acquisition of the CardioCel and VascuCel patch business from Admedus. The agreement includes the potential for us to pay up to

$7.8

million of additional consideration beyond payments made to date, with

$0.3

million contingent upon the delivery of audited financial statement of the acquired business to us;

$2.0

million contingent on LeMaitre Vascular’s success in obtaining CE marks on the acquired products,

$0.5

million contingent upon Admedus’ success in extending the shelf life of the acquired products as specified in the agreement, and another

$5.0

million contingent on the achievement of specified levels of revenues in the

first

and

months following the acquisition date. This additional contingent consideration was initially valued in total at

$2.0

million and will being re-measured each reporting period until the payment requirement ends, with any adjustments reported in income from operations. The following table provides a rollforward of the fair value of these liabilities, as determined by Level

unobservable inputs including management’s forecast of future revenues for the acquired business, as well as, management’s estimates of the likelihood of Obtaining CE marks on the acquired products, as well as of Admedus’ ability to extend the shelf life of the acquired products. The contingent payment related to the delivery of audited financial statements of the business was paid in

November 2019

upon satisfaction of the deliverable.

	Year ended December 31,
	2019			2018			2017
	(in thousands)
Beginning balance	$	72		$	1,300		$	1,320
Additions		1,989			-			-
Payments		(309	)		(1,199	)		(126	)
Change in fair value included in earnings		12			(29	)		106

Ending balance	$	1,764		$	72		$	1,300

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 14 - Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Quarterly Financial Information [Text Block]

. Quarterly Financial Data (unaudited)

	Three months ended
2019	March 31		June 30		September 30		December 31
	(in thousands, except per share data)
Total net sales	$	28,479	$	29,483	$	29,100	$	30,170
Gross profit		19,464		20,315		20,166		19,908
Income (loss) from operations		4,435		5,915		5,905		4,928
Net income		3,513		4,624		5,184		4,613
Earnings per share
Basic	$	0.18	$	0.23	$	0.26	$	0.23
Diluted	$	0.17	$	0.23	$	0.25	$	0.23

	Three months ended
2018	March 31		June 30		September 30		December 31
	(in thousands, except per share data)
Total net sales	$	25,994	$	27,020	$	24,165	$	28,389
Gross profit		18,474		18,992		17,255		19,218
Income (loss) from operations		4,862		11,541		4,613		7,193
Net income		3,853		8,751		4,314		6,025
Earnings per share
Basic	$	0.20	$	0.45	$	0.22	$	0.31
Diluted	$	0.19	$	0.43	$	0.21	$	0.30

Note 15 - Accumulated Other Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Comprehensive Income (Loss) Note [Text Block]

15.

Accumulated Other Comprehensive Income (Loss)

	Year ended December 31,
	2019			2018			2017
	(in thousands)
Beginning balance	$	(3,900	)	$	(2,289	)	$	(4,583	)

Other comprehensive income (loss) before reclassifications		(107	)		(1,611	)		2,294
Amounts reclassified from accumulated other comprehensive loss		-			-			-

Ending Balance	$	(4,007	)	$	(3,900	)	$	(2,289	)

Changes to our accumulated other comprehensive loss consisted primarily of foreign currency translation for the years ended

December 31, 2019,

2018

and

2017.

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Description of Business

single

Consolidation, Policy [Policy Text Block]

Consolidation and Basis of Presentation

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency Translation

Use of Estimates, Policy [Policy Text Block]

Estimates

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

January

2018

we adopted the provisions of ASU

2014

09,

Revenue from Contracts with Customers (Topic

606

)

. We used the modified retrospective method of adoption under which the comparative information was

not

restated and will continue to be reported under the standard in effect for those periods. The adoption of this standard was

not

material to our financial statements and there was

cumulative effect adjustment to the opening balance of retained earnings required. The core principle of Topic

606

Step

Identify the contract with a customer

Step

Identify the performance obligations in the contract

Step

Determine the transaction price

Step

Allocate the transaction price

Step

Recognize revenue when or as the entity satisfies a performance obligation

606

to account for these activities as fulfillment costs and

not

as performance obligations.

We generally reference customer purchase orders to determine the existence of a contract. Orders that are

not

one

or more, but

not

all, of the performance obligations.

	Year ended December 31,
	2019		2018
Americas	$	69,359	$	63,649
Europe, Middle East and Africa	$	39,480		35,319
Asia/Pacific Rim	$	8,393		6,600
Total	$	117,232	$	105,568

Except as discussed in Note

we do

not

carry any contract assets or contract liabilities, as there are generally

unbilled amounts due from customers under contracts for which we have partially satisfied performance obligations, or amounts received from customers for which we have

not

days of fulfillment of the orders, except in certain geographies such as Spain and Italy where the payment cycle is customarily longer. Accordingly, there is

Customers returning products

may

months remaining prior to its expiration date, or

twelve

months for our hospital customers in Europe, and generally be returned within

days of shipment. These return policies apply to sales to both hospitals and distributors. The amount of products returned to us, either for exchange or credit, has

not

been material. Nevertheless, we provide for an allowance for future sales returns based on historical return experience, which requires judgment. Our cost of replacing defective products has

not

been material and is accounted for at the time of replacement.

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expense

Shipping and Handling [Policy Text Block]

Shipping and Handling Costs

Shipping and handling fees paid by customers are recorded within net sales, with the related expense recorded in cost of sales.

Advertising Cost [Policy Text Block]

Advertising Costs

Advertising costs are expensed as incurred and are included as a component of sales and marketing expense in the accompanying consolidated statements of operations. Advertising costs are as follows:

	Year ended December 31,
	2019		2018		2017
			(in thousands)

Advertising expense	$	286	$	299	$	305

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

We consider all highly liquid instruments purchased with maturity dates of

days or less to be cash equivalents. Cash and cash equivalents are primarily invested in money market funds. These amounts are stated at cost, which approximates fair value.

Marketable Securities, Policy [Policy Text Block]

Short-term Marketable Securitie

Our short-term marketable securities are available-for-sale securities carried at fair value, with unrealized gains and losses recorded in other comprehensive income.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentrations of Credit Risk

$250,000.

Certain of our account balances exceed the FDIC limit. Cash balances held outside the United States totaled approximately

$9.0

million as of

December

31,

2019.

Our accounts receivable are with customers based in the United States and internationally. Accounts receivable generally are due within

may

range from

240

We closely monitor outstanding receivables for potential collection risks, including those that

may

be subject to significant payment delays due to government austerity measures impacting funding and payment practices. As of

December

31,

2019

our receivables in Italy and Spain totaled

$1.0

million and

$0.8

December

31,

2019,

if significant changes were to occur in the payment practices of these European governments or if government funding becomes unavailable, we

may

not

be able to collect on receivables due to us from these customers and our write offs of uncollectible amounts

may

increase.

	Balance at		Additions		Deductions		Balance at
	Beginning		(recoveries) charged		from		End of
	of Period		to Income		Reserves		Period
	(in thousands)
Allowance for doubtful accounts and sales returns:
Year ended December 31, 2019	$	399	$	388	$	265		522
Year ended December 31, 2018		349		264		214		399
Year ended December 31, 2017		258		230		139		349

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

not

material to our consolidated financial statements for the year ended

December 31, 2019.

Inventory and Other Deferred Costs [Policy Text Block]

Inventory and Other Deferred Costs

first

-in,

first

may

not

be accurate, and we

may

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using straight-line method as follows:

Description	Useful Life (Years)
Computers and equipment	3	–	5
Machinery and equipment	3	–	10
Leasehold improvements	The shorter of its useful life or lease term

Business Combinations Policy [Policy Text Block]

Valuation of Business Combinations

Contingent Consideration [Policy Text Block]

Contingent Consideration

Contingent consideration for acquisitions is recognized at the date of acquisition, based on the fair value at that date, and then re-measured periodically through adjustments to net income.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-lived Assets

may

indicate impairment include, but are

not

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

may

exist. We evaluate the

December

balance of the carrying value of goodwill based on a single reporting unit annually. We perform an assessment of qualitative factors to determine if it is “more likely than

not”

that the fair value of our reporting unit is less than its carrying value as a basis for determining whether it is necessary to perform the

two

-step goodwill impairment test. The “more likely than

not”

threshold is defined as having a likelihood of more than

goodwill impairment charges were required for the years ended

December

31,

2019,

2018

2017.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Other Intangible Assets

years.

Share-based Payment Arrangement [Policy Text Block]

Stock-based Compensation

We also issue restricted stock units (RSUs) as an additional form of equity compensation to our employees, officers, and directors, pursuant to our stockholder-approved

2006

Plan. RSUs entitle the grantee to an issuance of stock at

Commitments and Contingencies, Policy [Policy Text Block]

Commitments and Contingencies

may

December

31,

2019,

2018

and

2017,

we were

not

subject to any material litigation or claims and assessments.

Income Tax, Policy [Policy Text Block]

Income Taxes

not

that all or a portion of a deferred tax asset will

not

not”

fifty

percent likelihood of being realized upon ultimate settlement.

Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.

Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income

reclassifications out of comprehensive income for the years ended

December

31,

2019,

2018

2017.

Accumulated other comprehensive loss consisted primarily of foreign currency translation adjustment losses of

$4.0

million and

$3.9

million as of

December

31,

2019

and

2018,

respectively.

Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]

Restructuring

twelve

Earnings Per Share, Policy [Policy Text Block]

Earnings per Share

The computation of basic and diluted net income per share is as follows:

	Year ended December 31,
	2019		2018		2017
	(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	17,934	$	22,943	$	17,177

Weighted average shares outstanding		19,813		19,426		18,961

Basic earnings per share	$	0.91	$	1.18	$	0.91

Diluted:
Net income available for common stockholders	$	17,934	$	22,943	$	17,177

Weighted-average shares outstanding		19,813		19,426		18,961
Common stock equivalents, if dilutive		513		816		1,072


Shares used in computing diluted earnings per common share		20,326		20,242		20,033

Diluted earnings per share	$	0.88	$	1.13	$	0.86

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		468		230		6

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

January 1, 2019

we adopted the provisions of ASU

No.

2016

02,

Leases (Topic

842

subsequently amended by ASU

2018

11,

Leases (Topic

842

): Targeted Improvements

not

to apply the new lease standard to comparative periods but instead to recognize a cumulative-effect adjustment to retained earnings as of the date of adoption,

January 1, 2019.

Upon adoption of this standard, we recognized lease liabilities of

$7.0

million and right-of-use assets in the amount of

$6.5

million (net of the reversal of a previously recorded deferred rent liability of

$0.5

million). There was

cumulative-effect adjustment to retained earnings required. Additional disclosures required under the new standard are included in Note

to these financial statements.

June 2016,

the FASB issued ASU

2016

Financial Instruments – Credit Losses (Topic

326

January

2020.

The adoption of this standard is

not

August 2018,

the FASB issued ASU

2018

Fair Value Measurement (Topic

820

), which modifies the disclosure requirements for fair value measurements. The new standard is effective for us beginning

January

2020,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

January 2017,

the FASB issued ASU

2017

Intangibles – Goodwill and Other (Topic

350

), which, among other provisions, eliminates “step

2”

not

exceed the total amount of goodwill allocated to that reporting unit. The new standard is effective for us beginning

January

2020,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

December 2019,

the FASB issued ASU

2019

Income Taxes (Topic

740

), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic

740

as well as clarifying and amending other areas of existing GAAP under Topic

740.

The new standard is effective for us beginning

January

2021,

with early adoption permitted. The adoption of this standard is

not

expected to have a material impact on our financial statements.

Note 1 - Significant Accounting Policies and Related Matters (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Year ended December 31,
	2019		2018
Americas	$	69,359	$	63,649
Europe, Middle East and Africa	$	39,480		35,319
Asia/Pacific Rim	$	8,393		6,600
Total	$	117,232	$	105,568

Schedule of Advertising Expenses [Table Text Block]

	Year ended December 31,
	2019		2018		2017
			(in thousands)

Advertising expense	$	286	$	299	$	305

Financing Receivable, Allowance for Credit Loss [Table Text Block]

	Balance at		Additions		Deductions		Balance at
	Beginning		(recoveries) charged		from		End of
	of Period		to Income		Reserves		Period
	(in thousands)
Allowance for doubtful accounts and sales returns:
Year ended December 31, 2019	$	399	$	388	$	265		522
Year ended December 31, 2018		349		264		214		399
Year ended December 31, 2017		258		230		139		349

Schedule of Property, Plant and Equipment Estimated Useful Lives [Table Text Block]

Description	Useful Life (Years)
Computers and equipment	3	–	5
Machinery and equipment	3	–	10
Leasehold improvements	The shorter of its useful life or lease term

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Year ended December 31,
	2019		2018		2017
	(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	17,934	$	22,943	$	17,177

Weighted average shares outstanding		19,813		19,426		18,961

Basic earnings per share	$	0.91	$	1.18	$	0.91

Diluted:
Net income available for common stockholders	$	17,934	$	22,943	$	17,177

Weighted-average shares outstanding		19,813		19,426		18,961
Common stock equivalents, if dilutive		513		816		1,072


Shares used in computing diluted earnings per common share		20,326		20,242		20,033

Diluted earnings per share	$	0.88	$	1.13	$	0.86

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		468		230		6

Note 2 - Acquisitions and Divestitures (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

	Allocated
	Fair Value
	(in thousands)
Inventory and other	$	1,343
Intangible assets		8,725
Goodwill		7,344

Purchase price	$	17,412

	Allocated
	Fair Value
	(in thousands)
Inventory	$	276
Equipmentand supplies		70
Intangible assets		4,844
Goodwill		2,748

Purchase price	$	7,938

	Allocated
	Fair Value
	(in thousands)
Inventory	€	2,419
Land and building		750
Equipment and supplies		94
Intangible assets		623
Bargain purchase gain		(1,946	)

Purchase price	€	1,940

	Allocated
	Fair Value
	(in thousands)
Inventory	$	739
Equipment and supplies		416
Intangible assets		6,527
Goodwill		6,361

Purchase price	$	14,043

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

			Weighted
	Allocated		Average
	Fair Value		Useful Life (years)
	(in thousands)
Customer relationships	$	5,562	12.0
Intellectual property		2,335	8.0
Non-compete agreement		361	5.0
Tradenames		467	8.0

Total intangible assets	$	8,725

			Weighted
	Allocated		Average
	Fair Value		Useful Life (years)
	(in thousands)
Customer relationships	$	3,945	13.0
Intellectual property		563	7.0
Non-compete agreement		233	5.0
Tradenames		103	7.0

Total intangible assets	$	4,844

			Weighted
	Allocated		Average
	Fair Value		Useful Life (years)
	(in thousands)
Customer relationships	€	250	16.0
Intellectual property		237	5.0
Non-compete agreement		46	5.0
Tradenames		90	5.0

Total intangible assets	€	623

			Weighted
	Allocated		Average
	Fair Value		Useful Life (years)
	(in thousands)
Customer relationships	$	4,475	16.0
Intellectual property		1,316	7.0
Non-compete agreement		530	5.0
Tradenames		206	7.0

Total intangible assets	$	6,527

Disposal Groups, Including Discontinued Operations [Table Text Block]

	Allocated
	Fair Value
	(in thousands)
Inventory	$	308
Deferred revenue - transition services agreement		1,081
Goodwill		135
Gain on divestiture		5,876

Consideration received	$	7,400

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Note 3 - Inventories and Other Deferred Costs (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	December 31, 2019		December 31, 2018
	(in thousands)
Raw materials	$	5,359	$	4,085
Work-in-process		6,238		5,095
Finished products		23,032		16,391
Other deferred costs		4,898		1,817

Total inventory and other deferred costs	$	39,527	$	27,388

Note 4 - Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Property, Plant and Equipment [Table Text Block]

	As of December 31,
	2019			2018
	(in thousands)
Computers and equipment	$	4,623		$	4,077
Machinery and equipment		16,245			13,718
Building and leasehold improvements		11,758			11,651

Gross property and equipment		32,626			29,446
Less accumulated depreciation		(17,772	)		(15,344	)

Property and equipment, net	$	14,854		$	14,102

Depreciation Expense [Table Text Block]

	Year ended December 31,
	2019		2018		2017
			(in thousands)

Depreciation expense	$	2,979	$	2,564	$	2,266

Note 5 - Goodwill and Other Intangibles (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Goodwill [Table Text Block]

	As of December 31,
	2019			2018

Balance at beginning of year	$	29,868		$	23,844
Additions for acquisitions		10,092			6,361
Divestiture adjustment		-			(135	)
Effects of currency exchange		(9	)		(202	)

Balance at end of year	$	39,951		$	29,868

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	December 31, 2019						December 31, 2018
	Gross				Net		Gross				Net
	Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
	Value		Amortization		Value		Value		Amortization		Value
	(in thousands)
Product technology and intellectual property	$	13,502	$	5,722	$	7,780	$	11,728	$	5,726	$	6,002
Trademarks, tradenames and licenses		1,807		702		1,105		2,246		1,561		685
Customer relationships		18,215		3,364		14,851		10,065		3,806		6,259
Other intangible assets		1,725		568		1,157		2,145		1,399		746

Total identifiable intangible assets	$	35,249	$	10,356	$	24,893	$	26,184	$	12,492	$	13,692

Finite-lived Intangible Assets Amortization Expense [Table Text Block]

	Year ended December 31,
	2019		2018		2017
			(in thousands)

Amortization expense	$	2,437	$	1,760	$	1,790

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

	Year ended December 31,
	2020		2021		2022		2023		2024
	(in thousands)

Amortization expense	$	3,224	$	2,956	$	2,751	$	2,677	$	2,477

Note 6 - Accrued Expenses and Other Long-term Liabilities (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	December 31, 2019		December 31, 2018
	(in thousands)
Compensation and related taxes	$	8,550	$	7,973
Income and other taxes		1,003		2,927
Professional fees		40		43
Deferred revenue		-		552
Other		4,421		4,352

Total	$	14,014	$	15,847

Contract with Customer, Asset and Liability [Table Text Block]

	As of December 31,
	2019			2018

Beginning contract liability balance	$	552		$	-
Deferred revenue recorded		-			1,081
Revenue recognized upon satisfaction of performace obligations in the period		(552	)		(529	)

Ending balance	$	-		$	552

Other Noncurrent Liabilities [Table Text Block]

	December 31, 2019		December 31, 2018
	(in thousands)
Acquisition-related liabilities	$	3,268	$	1,326
Deferred rent		-		530
Income taxes		781		559
Other		166		196

Total	$	4,215	$	2,611

Note 7 - Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Lease, Cost [Table Text Block]

	Year ended
	December 31,
	2019
	(in thousands)

Lease cost
Operating lease cost	$	1,756
Short-term lease cost		291
Total lease cost	$	2,047

Other information
Cash paid for amounts included in the measurement of operating lease liabilities	$	1,858

Right-of-use assets obtained in exchange for new operating lease liabilities	$	10,571


Weighted average remaining lease term - operating leases (years)		8.3

Weighted average discount rate - operating leases		5.25	%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Year ending December 31,
2020	$	2,419
2021		2,351
2022		1,942
2023		1,686
2024		1,573
Thereafter		10,301
Adjustment to net present value as of December 31, 2019		(4,560	)

Minimum noncancelable lease liability	$	15,712

Note 8 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

	Year ended December 31,
	2019		2018		2017
	(in thousands)

United States	$	17,989	$	22,256	$	17,778
Foreign		3,690		6,188		3,328

Total	$	21,679	$	28,444	$	21,106

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	Year ended December 31,
	2019		2018			2017
			(in thousands)
Current:
Federal	$	1,501	$	4,262		$	2,451
State		304		673			292
Foreign		1,116		2,718			886

		2,921		7,653			3,629
Deferred:
Federal		538		(1,512	)		(268	)
State		144		(145	)		390
Foreign		142		(495	)		178

		824		(2,152	)		300

Provision for income taxes	$	3,745	$	5,501		$	3,929

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]

	2019		2018		2017
	(in thousands)
Unrecognized tax benefits at the beginning of year	$	711	$	525	$	390
Additions for tax positions of current year		74		73		83
Additions for tax positions of prior years		63		113		57
Reductions for settlements with taxing authorities.		-		-		-
Reductions for lapses of the applicable statutes of limitations		-		-		(5	)
Unrecognized tax benefits at the end of the year	$	848	$	711	$	525

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	As of December 31,
	2019			2018
	(in thousands)
Deferred tax assets:
Inventory	$	840		$	976
Net operating loss carryforwards		1,289			1,421
Tax credit carryforwards		944			828
Capital loss carryforwards		277			279
Reserves and accruals		787			802
Operating lease liabilities		3,343			-
Intangible assets		2,764			2,737
Stock options		342			373
Other		20			91

Total deferred tax assets		10,606			7,507

Deferred tax liabilities:
Property and equipment		(1,520	)		(1,416	)
Goodwill		(3,459	)		(3,023	)
Operating lease right-of-use assets		(3,224	)		-
Foreign branch deferred offset		(923	)		(1,032	)
Other		(187	)		(50	)

Total deferred tax liabilities		(9,313	)		(5,521	)

Net deferred tax assets before valuation allowance		1,293			1,986

Valuation allowance		(1,388	)		(1,255	)

Net deferred tax liabiltity	$	(95	)	$	731

Deferred tax classification
Long-term deferred tax asset	$	1,084		$	1,215
Long-term deferred tax liability		(1,179	)		(484	)

Net long-term deferred tax liability	$	(95	)	$	731

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	2019			2018			2017

Federal statutory rate		21.0	%		21.0	%		35.0	%
State tax, net of federal benefit		1.9	%		1.4	%		1.7	%
Effect of foreign taxes		2.1	%		3.8	%		(0.6%	)
Federal tax on foreign income		0.8	%		1.4	%		1.7	%
Valuation allowance		0.6	%		(3.2%	)		0.1	%
Foreign deferred tax liability offset		(0.4%	)		(0.3%	)		(0.2%	)
Manufacturing deduction		0.0	%		0.0	%		(1.5%	)
Research & development tax credits		(1.2%	)		(0.7%	)		(0.6%	)
Stock options		(8.8%	)		(3.3%	)		(15.8%	)
Uncertain tax positions		1.0	%		0.8	%		0.6	%
Other permanent differences		0.5	%		(0.7%	)		1.0	%
Change in tax laws		0.0	%		0.0	%		2.9	%
Deferred tax remeasurement		0.0	%		0.0	%		(5.0%	)
Other		(0.2%	)		(0.9%	)		(0.7%	)

Effective tax rate		17.3	%		19.3	%		18.6	%

Summary of Income Tax Examinations [Table Text Block]

United States	2016 and forward
Foreign	2012 and forward

Note 9 - Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	2019			2018			2017
Dividend yield		0.96	%		1.20	%		0.70	%
Volatility		42.8	%		41.3	%		39.1	%
Risk-free interest rate		1.7	%		2.7	%		2.2	%
Weighted average expected option term (in years)		4.7			4.8			4.6
Weighted average fair value per share of options granted	$	12.51		$	8.28		$	10.37

Share-based Payment Arrangement, Option, Activity [Table Text Block]

				Weighted		Weighted Average	Aggregate
	Number			Average		Remaining	Intrinsic
	of Shares			Exercise Price		Contractual Term	Value
						(in years)
Balance outstanding at December 31, 2018 (1)		1,462,575		$	16.41	4.54	$	12,214,422

Granted		195,379		$	35.53
Exercised (2)		(509,693	)	$	9.53		$	11,488,292
Canceled / Expired		(101,167	)	$	17.90
Balance outstanding at December 31, 2019 (3)		1,047,094		$	23.19	4.31	$	13,366,595

Vested and exercisable at December 31, 2019 (4)		309,501		$	19.64	3.50	$	5,046,733
Expected to vest at December 31, 2019		737,593		$	24.68	4.65
Total		1,047,094

Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

				Weighted
				Average
				Grant Date
	Shares			Fair Value

Balance outstanding at December 31, 2018		217,895		$	21.21

Granted		56,567		$	35.41
Vested (1)		(61,058	)	$	18.46
Canceled		(24,723	)	$	22.19

Balance outstanding at December 31, 2019		188,681		$	26.14

Accelerated Share Repurchases [Table Text Block]

	2019		2018

Shares of common stock repurchased		20,524		21,410
Average per share repurchase price	$	33.28	$	34.62
Aggregage purchase price (in thousands)	$	683	$	741

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	2019		2018		2017
	(in thousands)
Stock option awards	$	1,580	$	1,457	$	1,612
Restricted stock units		1,062		892		644

Total stock-based compensation	$	2,642	$	2,349	$	2,256

	2019		2018		2017
	(in thousands)
Cost of sales	$	310	$	272	$	188
Sales and marketing		544		529		403
General and administrative		1,509		1,293		1,484
Research and development		279		255		181

Total stock-based compensation	$	2,642	$	2,349	$	2,256

Schedule of Dividends Payable [Table Text Block]

Record Date	Payment Date	Per Share Amount		Dividend Payment
				(in thousands)
Fiscal Year 2019
March 22, 2019	April 5, 2019	$	0.085	$	1,672
May 22, 2019	June 6, 2019	$	0.085	$	1,672
August 21, 2019	September 5, 2019	$	0.085	$	1,691
November 20, 2019	December 5, 2019	$	0.085	$	1,701


Fiscal Year 2018
March 22, 2018	April 5, 2018	$	0.070	$	1,351
May 22, 2018	June 7, 2018	$	0.070	$	1,353
August 22, 2018	September 6, 2018	$	0.070	$	1,369
November 20, 2018	December 6, 2018	$	0.070	$	1,372

Note 11 - Segment and Enterprise-wide Disclosures (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]

	Year ended December 31,
	2019		2018		2017
	(in thousands)

United States	$	63,130	$	59,078	$	58,470
Germany		12,400		12,445		11,576
Other countries		41,702		34,045		30,821

Net sales	$	117,232	$	105,568	$	100,867

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

	As of December 31,
	2019		2018
	(in thousands)

United States	$	24,885	$	11,006
Australia		1,499		1,460
France		1,089		1,071
Germany		1,405		430
Other countries		1,184		135

Total long-term assets	$	30,062	$	14,102

Note 12 - Supplemental Cash Flow Information (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]

	Year ended December 31,
	2019		2018		2017
	(in thousands)
Cash paid for income taxes, net	$	4,817	$	5,521	$	3,146

Note 13 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Year ended December 31,
	2019			2018			2017
	(in thousands)
Beginning balance	$	72		$	1,300		$	1,320
Additions		1,989			-			-
Payments		(309	)		(1,199	)		(126	)
Change in fair value included in earnings		12			(29	)		106

Ending balance	$	1,764		$	72		$	1,300

Note 14 - Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Quarterly Financial Information [Table Text Block]

	Three months ended
2019	March 31		June 30		September 30		December 31
	(in thousands, except per share data)
Total net sales	$	28,479	$	29,483	$	29,100	$	30,170
Gross profit		19,464		20,315		20,166		19,908
Income (loss) from operations		4,435		5,915		5,905		4,928
Net income		3,513		4,624		5,184		4,613
Earnings per share
Basic	$	0.18	$	0.23	$	0.26	$	0.23
Diluted	$	0.17	$	0.23	$	0.25	$	0.23

	Three months ended
2018	March 31		June 30		September 30		December 31
	(in thousands, except per share data)
Total net sales	$	25,994	$	27,020	$	24,165	$	28,389
Gross profit		18,474		18,992		17,255		19,218
Income (loss) from operations		4,862		11,541		4,613		7,193
Net income		3,853		8,751		4,314		6,025
Earnings per share
Basic	$	0.20	$	0.45	$	0.22	$	0.31
Diluted	$	0.19	$	0.43	$	0.21	$	0.30

Note 15 - Accumulated Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Year ended December 31,
	2019			2018			2017
	(in thousands)
Beginning balance	$	(3,900	)	$	(2,289	)	$	(4,583	)

Other comprehensive income (loss) before reclassifications		(107	)		(1,611	)		2,294
Amounts reclassified from accumulated other comprehensive loss		-			-			-

Ending Balance	$	(4,007	)	$	(3,900	)	$	(2,289	)

Note 1 - Significant Accounting Policies and Related Matters (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Jan. 01, 2019 USD ($)
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 16,572	$ 15,721
Goodwill, Impairment Loss	0	0	$ 0
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0	$ 0
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Ending Balance	4,000	3,900
Operating Lease, Liability, Total	15,712
Operating Lease, Right-of-Use Asset	$ 15,208
Number of Operating Segments	1
Accounting Standards Update 2016-02 [Member]
Operating Lease, Liability, Total				$ 7,000
Operating Lease, Right-of-Use Asset				6,500
Accrued Rent				$ (500)
ITALY
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 1,000
SPAIN
Accounts Receivable, after Allowance for Credit Loss, Current, Total	800
Geographic Distribution, Foreign [Member]
Cash, Ending Balance	$ 9,000
Minimum [Member]
Period of Payments Received from Customers	30 days
Finite-Lived Intangible Asset, Useful Life	2 years
Maximum [Member]
Period of Payments Received from Customers	60 days
Finite-Lived Intangible Asset, Useful Life	16 years

Note 1 - Significant Accounting Policies and Related Matters - Disaggregation of Revenue by Major Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue	$ 117,232	$ 105,568
Americas [Member]
Revenue	69,359	63,649
EMEA [Member]
Revenue	39,480	35,319
Asia Pacific [Member]
Revenue	$ 8,393	$ 6,600

Note 1 - Significant Accounting Policies and Related Matters - Summary of Advertising Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Advertising expense	$ 286	$ 299	$ 305

Note 1 - Significant Accounting Policies and Related Matters - Allowance for Doubtful Accounts and Sales Returns (Details) - Allowance for Doubtful Accounts and Sales Returns [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Balance	$ 399	$ 349	$ 258
Additions (recoveries) charged to income	388	264	230
Deductions from reserves	265	214	139
Balance	$ 522	$ 399	$ 349

Note 1 - Significant Accounting Policies and Related Matters - Summary of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2019
Computers and Equipment [Member] \| Minimum [Member]
Useful life (Year)	3 years
Computers and Equipment [Member] \| Maximum [Member]
Useful life (Year)	5 years
Machinery and Equipment [Member] \| Minimum [Member]
Useful life (Year)	3 years
Machinery and Equipment [Member] \| Maximum [Member]
Useful life (Year)	10 years
Leasehold Improvements [Member]
Estimated useful life	The shorter of its useful life or lease term

Note 1 - Significant Accounting Policies and Related Matters - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Basic:
Net income available for common stockholders	$ 4,613	$ 5,184	$ 4,624	$ 3,513	$ 6,025	$ 4,314	$ 8,751	$ 3,853	$ 17,934	$ 22,943	$ 17,177
Weighted average shares outstanding (in shares)									19,813	19,426	18,961
Basic earnings per share (in dollars per share)	$ 0.23	$ 0.26	$ 0.23	$ 0.18	$ 0.31	$ 0.22	$ 0.45	$ 0.20	$ 0.91	$ 1.18	$ 0.91
Diluted:
Net income available for common stockholders	$ 4,613	$ 5,184	$ 4,624	$ 3,513	$ 6,025	$ 4,314	$ 8,751	$ 3,853	$ 17,934	$ 22,943	$ 17,177
Weighted average shares outstanding (in shares)									19,813	19,426	18,961
Common stock equivalents, if dilutive (in shares)									513	816	1,072
Shares used in computing diluted earnings per common share (in shares)									20,326	20,242	20,033
Diluted earnings per share (in dollars per share)	$ 0.23	$ 0.25	$ 0.23	$ 0.17	$ 0.30	$ 0.21	$ 0.43	$ 0.19	$ 0.88	$ 1.13	$ 0.86
Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive (in shares)									468	230	6

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Note 2 - Acquisitions and Divestitures (Details Textual) $ in Thousands, € in Millions							3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Oct. 11, 2019 USD ($)	Jul. 12, 2019 USD ($)	Oct. 22, 2018 USD ($)	Oct. 22, 2018 EUR (€)	Sep. 20, 2018 USD ($)	Apr. 05, 2018 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2019	Oct. 22, 2018 EUR (€)
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life										10 years 36 days
Reddick Divestiture [Member]
Proceeds from Sale of Productive Assets, Total						$ 7,400
Long-term Purchase Commitment, Period						2 years
Gain (Loss) on Disposition of Assets for Financial Service Operations, Total									$ 5,900
CardioCel and VascuCel Biologic Patches [Member]
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual							$ 1,400
Payments to Acquire Businesses, Gross	$ 14,200
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period	15 years
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years 146 days
CardioCel and VascuCel Biologic Patches [Member] \| Achieving Audited Financial Statements of Acquired Business [Member]
Payments to Acquire Businesses, Gross	$ 300
CardioCel and VascuCel Biologic Patches [Member] \| First Holdback [Member]
Business Combination, Contingent Consideration, Liability, Total	700
CardioCel and VascuCel Biologic Patches [Member] \| Second Holdback [Member]
Business Combination, Contingent Consideration, Liability, Total	700
CardioCel and VascuCel Biologic Patches [Member] \| Third Holdback [Member]
Business Combination, Contingent Consideration, Liability, Total	2,000
CardioCel and VascuCel Biologic Patches [Member] \| Revenues Exceeding Twenty Million in the First Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	2,500
CardioCel and VascuCel Biologic Patches [Member] \| Revenues Exceeding Fifteen Million in the First Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	1,200
CardioCel and VascuCel Biologic Patches [Member] \| Revenues Exceeding Thirty Million in the Second Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	2,500
CardioCel and VascuCel Biologic Patches [Member] \| Revenues Exceeding Twenty-Two and a Half Million in the First Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	1,200
CardioCel and VascuCel Biologic Patches [Member] \| Extension of Product Shelf Life from 36 Months to 60 Months in the First Anniversary of Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	500
CardioCel and VascuCel Biologic Patches [Member] \| Technology Licenses [Member]
Business Combination, Consideration Transferred, Total	8,000
CardioCel and VascuCel Biologic Patches [Member] \| Maximum [Member] \| Biological Patch Business Assets [Member]
Business Combination, Consideration Transferred, Total	$ 15,300
Tru-Incise Valve Cutter [Member]
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual								$ 800
Business Combination, Consideration Transferred, Total		$ 8,000
Payments to Acquire Businesses, Gross		$ 6,800
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period		15 years
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		11 years 292 days
Business Combination, Deferred Purchase Consideration, Installment Payment		$ 400
Business Combination, Deferred Purchase Consideration		1,200
Acquisition Date Fair Value		$ 1,100
Business Combination ,Fair Value Inputs, Discount Rate		4.19%
Cardial [Member]
Business Combination, Consideration Transferred, Total			$ 2,300	€ 2.0
Payments to Acquire Businesses, Gross			$ 1,300	€ 1.1
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			9 years 146 days	9 years 146 days
Business Combination, Deferred Purchase Consideration			$ 400								€ 0.4
Business Combination, Consideration Transferred, Liabilities Incurred			500	€ 0.5
Deferred Tax Assets, Business Combinations			600								€ 0.5
Business Combination, Bargain Purchase, Gain Recognized, Amount			$ 1,600	€ 1.4
Applied Medical [Member]
Business Combination, Consideration Transferred, Total					$ 14,200
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period					15 years
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life					13 years
Acquisition Date Fair Value					$ 3,043
Business Combination ,Fair Value Inputs, Discount Rate					3.75%
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Deferred Costs					$ 3,200
Applied Medical [Member] \| UNITED STATES
Percentage of Sales by Major Product Lines					60.00%
Applied Medical [Member] \| Foreign [Member]
Percentage of Sales by Major Product Lines					40.00%
Applied Medical [Member] \| Closing Date [Member]
Business Combination, Consideration Transferred, Total					$ 11,000
Applied Medical [Member] \| 12 Months Following the Closing Date [Member]
Business Combination, Consideration Transferred, Total					2,000
Applied Medical [Member] \| 24 Months Following the Closing Date [Member]
Business Combination, Consideration Transferred, Total					$ 1,200
Balloon Supply Agreement [Member] \| Reddick Divestiture [Member]
Long-term Purchase Commitment, Period						6 years

Note 2 - Acquisitions and Divestitures - Assets Acquired and Liabilities Assumed (Details) € in Thousands, $ in Thousands	Dec. 31, 2019 USD ($)	Oct. 11, 2019 USD ($)	Jul. 12, 2019 USD ($)	Dec. 31, 2018 USD ($)	Oct. 22, 2018 EUR (€)	Sep. 20, 2018 USD ($)	Dec. 31, 2017 USD ($)
Goodwill	$ 39,951			$ 29,868			$ 23,844
Goodwill	$ 39,951			$ 29,868			$ 23,844
CardioCel and VascuCel Biologic Patches [Member]
Inventory and other		$ 1,343
Intangible assets		8,725
Goodwill		7,344
Purchase price		17,412
Intangible assets		8,725
Goodwill		$ 7,344
Tru-Incise Valve Cutter [Member]
Intangible assets			$ 4,844
Goodwill			2,748
Purchase price			7,938
Inventory			276
Equipmentand supplies			70
Intangible assets			4,844
Goodwill			$ 2,748
Cardial [Member]
Intangible assets \| €					€ 623
Purchase price \| €					1,940
Inventory \| €					2,419
Equipmentand supplies \| €					94
Intangible assets \| €					623
Land and building \| €					750
Bargain purchase gain \| €					€ (1,946)
Applied Medical [Member]
Intangible assets						$ 6,527
Goodwill						6,361
Purchase price						14,043
Inventory						739
Equipmentand supplies						416
Intangible assets						6,527
Goodwill						$ 6,361

Note 2 - Acquisitions and Divestitures - Acquired Intangible Assets and Related Estimated Useful Lives (Details) € in Thousands, $ in Thousands					12 Months Ended
	Oct. 11, 2019 USD ($)	Jul. 12, 2019 USD ($)	Oct. 22, 2018 EUR (€)	Sep. 20, 2018 USD ($)	Dec. 31, 2019
Weighted Average Useful Life (Year)					10 years 36 days
CardioCel and VascuCel Biologic Patches [Member]
Intangible assets	$ 8,725
Weighted Average Useful Life (Year)	10 years 146 days
CardioCel and VascuCel Biologic Patches [Member] \| Customer Relationships [Member]
Intangible assets	$ 5,562
Weighted Average Useful Life (Year)	12 years
CardioCel and VascuCel Biologic Patches [Member] \| Intellectual Property [Member]
Intangible assets	$ 2,335
Weighted Average Useful Life (Year)	8 years
CardioCel and VascuCel Biologic Patches [Member] \| Noncompete Agreements [Member]
Intangible assets	$ 361
Weighted Average Useful Life (Year)	5 years
CardioCel and VascuCel Biologic Patches [Member] \| Trade Names [Member]
Intangible assets	$ 467
Weighted Average Useful Life (Year)	8 years
Tru-Incise Valve Cutter [Member]
Intangible assets		$ 4,844
Weighted Average Useful Life (Year)		11 years 292 days
Tru-Incise Valve Cutter [Member] \| Customer Relationships [Member]
Intangible assets		$ 3,945
Weighted Average Useful Life (Year)		13 years
Tru-Incise Valve Cutter [Member] \| Intellectual Property [Member]
Intangible assets		$ 563
Weighted Average Useful Life (Year)		7 years
Tru-Incise Valve Cutter [Member] \| Noncompete Agreements [Member]
Intangible assets		$ 233
Weighted Average Useful Life (Year)		5 years
Tru-Incise Valve Cutter [Member] \| Trade Names [Member]
Intangible assets		$ 103
Weighted Average Useful Life (Year)		7 years
Cardial [Member]
Intangible assets \| €			€ 623
Weighted Average Useful Life (Year)			9 years 146 days
Cardial [Member] \| Customer Relationships [Member]
Intangible assets \| €			€ 250
Weighted Average Useful Life (Year)			16 years
Cardial [Member] \| Intellectual Property [Member]
Intangible assets \| €			€ 237
Weighted Average Useful Life (Year)			5 years
Cardial [Member] \| Noncompete Agreements [Member]
Intangible assets \| €			€ 46
Weighted Average Useful Life (Year)			5 years
Cardial [Member] \| Trade Names [Member]
Intangible assets \| €			€ 90
Weighted Average Useful Life (Year)			5 years
Applied Medical [Member]
Intangible assets				$ 6,527
Weighted Average Useful Life (Year)				13 years
Applied Medical [Member] \| Customer Relationships [Member]
Intangible assets				$ 4,475
Weighted Average Useful Life (Year)				16 years
Applied Medical [Member] \| Intellectual Property [Member]
Intangible assets				$ 1,316
Weighted Average Useful Life (Year)				7 years
Applied Medical [Member] \| Noncompete Agreements [Member]
Intangible assets				$ 530
Weighted Average Useful Life (Year)				5 years
Applied Medical [Member] \| Trade Names [Member]
Intangible assets				$ 206
Weighted Average Useful Life (Year)				7 years

Note 2 - Acquisitions and Divestitures - Asset Purchase Agreement (Details) - Reddick Divestiture [Member] $ in Thousands	Apr. 05, 2018 USD ($)
Inventory	$ 308
Deferred revenue - transition services agreement	1,081
Goodwill	135
Gain on divestiture	5,876
Consideration received	$ 7,400

Note 3 - Inventories and Other Deferred Costs (Details Textual) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross	$ 1.9	$ 1.7

Note 3 - Inventories and Other Deferred Costs - Summary of Inventories and Other Deferred Costs (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Raw materials	$ 5,359	$ 4,085
Work-in-process	6,238	5,095
Finished products	23,032	16,391
Other deferred costs	4,898	1,817
Total inventory and other deferred costs	$ 39,527	$ 27,388

Note 4 - Property and Equipment (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Impairment of Long-Lived Assets Held-for-use	$ 0.5	$ 1.0	$ 0.2

Note 4 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Gross property and equipment	$ 32,626	$ 29,446
Less accumulated depreciation	(17,772)	(15,344)
Property and equipment, net	14,854	14,102
Computers and Equipment [Member]
Gross property and equipment	4,623	4,077
Machinery and Equipment [Member]
Gross property and equipment	16,245	13,718
Building and Leasehold Improvements [Member]
Gross property and equipment	$ 11,758	$ 11,651

Note 4 - Property and Equipment - Depreciation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Depreciation expense	$ 2,979	$ 2,564	$ 2,266

Note 5 - Goodwill and Other Intangibles (Details Textual) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years 36 days
Impairment of Intangible Assets, Finite-lived	$ 4.5
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	2 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	16 years

Note 5 - Goodwill and Other Intangibles - Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Balance at beginning of year	$ 29,868	$ 23,844
Additions for acquisitions	10,092	6,361
Divestiture adjustment		(135)
Effects of currency exchange	(9)	(202)
Balance at end of year	$ 39,951	$ 29,868

Note 5 - Goodwill and Other Intangibles - Components of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Gross carrying value	$ 35,249	$ 26,184
Accumulated amortization	10,356	12,492
Net carrying value	24,893	13,692
Product Technology and Intellectual Property [Member]
Gross carrying value	13,502	11,728
Accumulated amortization	5,722	5,726
Net carrying value	7,780	6,002
Trademarks, Tradenames and Licenses [Member]
Gross carrying value	1,807	2,246
Accumulated amortization	702	1,561
Net carrying value	1,105	685
Customer Relationships [Member]
Gross carrying value	18,215	10,065
Accumulated amortization	3,364	3,806
Net carrying value	14,851	6,259
Other Intangible Assets [Member]
Gross carrying value	1,725	2,145
Accumulated amortization	568	1,399
Net carrying value	$ 1,157	$ 746

Note 5 - Goodwill and Other Intangibles - Amortization Expense Included in General and Administrative Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Amortization expense	$ 2,437	$ 1,760	$ 1,790

Note 5 - Goodwill and Other Intangibles - Estimated Amortization Expense for Each of Five Succeeding Fiscal Years (Details) $ in Thousands	Dec. 31, 2019 USD ($)
2020	$ 3,224
2021	2,956
2022	2,751
2023	2,677
2024	$ 2,477

Note 6 - Accrued Expenses and Other Long-term Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Compensation and related taxes	$ 8,550	$ 7,973
Income and other taxes	1,003	2,927
Professional fees	40	43
Deferred revenue		552
Other	4,421	4,352
Total	$ 14,014	$ 15,847

Note 6 - Accrued Expenses and Other Long-term Liabilities - Deferred Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Contract liability balance	$ 552
Deferred revenue recorded		1,081
Revenue recognized upon satisfaction of performace obligations in the period	(552)	(529)
Contract liability balance		$ 552

Note 6 - Accrued Expenses and Other Long-term Liabilities - Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Acquisition-related liabilities	$ 3,268	$ 1,326
Deferred rent		530
Income taxes	781	559
Other	166	196
Total	$ 4,215	$ 2,611

Note 7 - Commitments and Contingencies (Details Textual) $ in Thousands	Dec. 31, 2019 USD ($) ft²
Finance Lease, Right-of-Use Asset \| $	$ 0
Lessee, Operating Lease, Discount Rate	5.25%
Recorded Unconditional Purchase Obligation, Total \| $	$ 1,500
Leased Automobiles [Member]
Lessee, Operating Lease, Term of Contract	3 years
GERMANY
Lessee, Operating Lease, Renewal Term	5 years
CANADA
Lessee, Operating Lease, Renewal Term	5 years
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility One [Member]
Area of Real Estate Property	27,098
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Two [Member]
Area of Real Estate Property	27,289
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Three [Member]
Area of Real Estate Property	15,642
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Four [Member] \| Massachusetts [Member]
Area of Real Estate Property	12,878
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Five [Member] \| Massachusetts [Member]
Area of Real Estate Property	26,447
United Kingdom Sales and Distribution Business [Member] \| Hereford, England [Member]
Area of Real Estate Property	2,258
International Operations Headquarter Facility [Member] \| GERMANY
Area of Real Estate Property	16,470
Additional Area of Real Estate Property Added	3,630

Note 7 - Commitments and Contingencies - Additional Lease Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Operating lease cost	$ 1,756
Short-term lease cost	291
Total lease cost	2,047
Cash paid for amounts included in the measurement of operating lease liabilities	1,858
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 10,571
Weighted average remaining lease term - operating leases (years) (Year)	8 years 109 days
Weighted average discount rate - operating leases	5.25%

Note 7 - Commitments and Contingencies - Minimum Rental Commitments (Details) $ in Thousands	Dec. 31, 2019 USD ($)
2020	$ 2,419
2021	2,351
2022	1,942
2023	1,686
2024	1,573
Thereafter	10,301
Adjustment to net present value as of December 31, 2019	(4,560)
Operating Lease, Liability, Total	$ 15,712

Note 8 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Unrecognized Tax Benefits, Ending Balance	$ 848	$ 711	$ 525	$ 390
Deferred Tax Assets, Valuation Allowance, Total	1,388	1,255
Deferred Tax Assets, Operating Loss Carryforwards, Total	1,289	1,421
Deferred Tax Assets, Capital Loss Carryforwards	277	279
State and Local Jurisdiction [Member]
Tax Credit Carryforward, Amount	1,500
State and Local Jurisdiction [Member] \| Internal Revenue Service (IRS) [Member]
Tax Adjustments, Settlements, and Unusual Provisions			$ 200
Foreign Tax Authority [Member] \| AUSTRALIA
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	100	$ (700)
Deferred Tax Assets, Operating Loss Carryforwards, Total	1,200
Deferred Tax Assets, Capital Loss Carryforwards	900
Foreign Tax Authority [Member] \| FRANCE
Deferred Tax Assets, Operating Loss Carryforwards, Total	2,500
Foreign Tax Authority [Member] \| SPAIN
Deferred Tax Assets, Operating Loss Carryforwards, Total	900
Foreign Tax Authority [Member] \| NORWAY
Deferred Tax Assets, Operating Loss Carryforwards, Total	$ 100

Note 8 - Income Taxes - Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
United States	$ 17,989	$ 22,256	$ 17,778
Foreign	3,690	6,188	3,328
Total	$ 21,679	$ 28,444	$ 21,106

Note 8 - Income Taxes - The Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current:
Federal	$ 1,501	$ 4,262	$ 2,451
State	304	673	292
Foreign	1,116	2,718	886
	2,921	7,653	3,629
Deferred:
Federal	538	(1,512)	(268)
State	144	(145)	390
Foreign	142	(495)	178
	824	(2,152)	300
Provision for income taxes	$ 3,745	$ 5,501	$ 3,929

Note 8 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Unrecognized tax benefits at the beginning of year	$ 711	$ 525	$ 390
Additions for tax positions of current year	74	73	83
Additions for tax positions of prior years	63	113	57
Reductions for settlements with taxing authorities.
Reductions for lapses of the applicable statutes of limitations			(5)
Unrecognized tax benefits at the end of the year	$ 848	$ 711	$ 525

Note 8 - Income Taxes - Deferred Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Inventory	$ 840	$ 976
Net operating loss carryforwards	1,289	1,421
Tax credit carryforwards	944	828
Capital loss carryforwards	277	279
Reserves and accruals	787	802
Operating lease liabilities	3,343
Intangible assets	2,764	2,737
Stock options	342	373
Other	20	91
Total deferred tax assets	10,606	7,507
Deferred tax liabilities:
Property and equipment	(1,520)	(1,416)
Goodwill	(3,459)	(3,023)
Operating lease right-of-use assets	(3,224)
Foreign branch deferred offset	(923)	(1,032)
Other	(187)	(50)
Total deferred tax liabilities	(9,313)	(5,521)
Net deferred tax assets before valuation allowance	1,293	1,986
Valuation allowance	(1,388)	(1,255)
Net deferred tax liability	(95)
Net deferred tax asset		731
Deferred tax classification
Deferred tax assets	1,084	1,215
Long-term deferred tax liability	(1,179)	(484)
Net long-term deferred tax liability	$ (95)
Net long-term deferred tax asset		$ 731

Note 8 - Income Taxes - Reconciliation of the Federal Statutory Rate to Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Federal statutory rate	21.00%	21.00%	35.00%
State tax, net of federal benefit	1.90%	1.40%	1.70%
Effect of foreign taxes	2.10%	3.80%	(0.60%)
Federal tax on foreign income	0.80%	1.40%	1.70%
Valuation allowance	0.60%	(3.20%)	0.10%
Foreign deferred tax liability offset	(0.40%)	(0.30%)	(0.20%)
Manufacturing deduction	0.00%	0.00%	(1.50%)
Research & development tax credits	(1.20%)	(0.70%)	(0.60%)
Stock options	(8.80%)	(3.30%)	(15.80%)
Uncertain tax positions	1.00%	0.80%	0.60%
Other permanent differences	0.50%	(0.70%)	1.00%
Change in tax laws	0.00%	0.00%	2.90%
Deferred tax remeasurement	0.00%	0.00%	(5.00%)
Other	(0.20%)	(0.90%)	(0.70%)
Effective tax rate	17.30%	19.30%	18.60%

Note 8 - Income Taxes - Summary of Tax Years Subject to Examination in Most Significant Tax Jurisdictions (Details)	12 Months Ended
	Dec. 31, 2019
Domestic Tax Authority [Member]
Income tax year under examination	2016 2017 2018 2019
Foreign Tax Authority [Member]
Income tax year under examination	2012 2013 2014 2015 2016 2017 2018 2019

Note 9 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Millions		11 Months Ended	12 Months Ended
	Feb. 13, 2020	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Feb. 14, 2019
Common Stock, Shares Authorized		37,000,000	37,000,000	37,000,000
Preferred Stock, Shares Authorized		3,000,000	3,000,000	3,000,000
Preferred Stock, Shares Outstanding, Ending Balance		0	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized			5,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		7,118,003	7,118,003
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		1,089,749	1,089,749
Share Price		$ 35.95	$ 35.95	$ 23.64
Common Stock, Dividends, Per Share, Declared			$ 0.34	$ 0.28	$ 0.22
Subsequent Event [Member]
Common Stock, Dividends, Per Share, Declared	$ 0.095
Dividends Payable	$ 1.9
Dividends Payable, Date Declared	Feb. 13, 2020
Dividends Payable, Date to be Paid	Mar. 19, 2020
Dividends Payable, Date of Record	Mar. 03, 2020
Stock Repurchase Program [Member] \| Common Stock [Member]
Stock Repurchase Program, Authorized Amount						$ 10.0
Treasury Stock, Shares, Acquired		0
Share-based Payment Arrangement, Option [Member] \| Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years
Share-based Payment Arrangement, Option [Member] \| Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			5 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value			$ 2.1	$ 1.9	$ 1.9
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 10.4	$ 10.4
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			3 years 292 days

Note 9 - Stockholders' Equity - Weighted Average Assumptions (Details) - Share-based Payment Arrangement, Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Dividend yield	0.96%	1.20%	0.70%
Volatility	42.80%	41.30%	39.10%
Risk-free interest rate	1.70%	2.70%	2.20%
Weighted average expected option term (Year)	4 years 255 days	4 years 292 days	4 years 219 days
Weighted average fair value per share of options granted (in dollars per share)	$ 12.51	$ 8.28	$ 10.37

Note 9 - Stockholders' Equity - Summary of Option Activity (Details) - USD ($)

12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

^[1]

Outstanding (in shares)

^[1]

1,462,575

Outstanding, weighted average exercise price (in dollars per share)

^[1]

$ 16.41

Outstanding, weighted average contractual term (Year)

4 years 113 days

^[2]

4 years 197 days

Outstanding, aggregate intrinsic value

$ 13,366,595

^[2]

$ 12,214,422

Granted (in shares)

195,379

Granted, weighted average exercise price (in dollars per share)

$ 35.53

Exercised (in shares)

^[3]

(509,693)

Exercised, weighted average exercise price (in dollars per share)

^[3]

$ 9.53

Exercised, aggregate intrinsic value

^[3]

$ 11,488,292

Canceled / Expired (in shares)

(101,167)

Canceled / Expired, weighted average exercise price (in dollars per share)

$ 17.90

Outstanding (in shares)

1,047,094

^[2]

1,462,575

Outstanding, weighted average exercise price (in dollars per share)

$ 23.19

^[2]

$ 16.41

Vested and exercisable (in shares)

^[4]

309,501

Vested and exercisable, weighted average exercise price (in dollars per share)

^[4]

$ 19.64

Vested and exercisable, weighted average contractual term (Year)

^[4]

3 years 182 days

Vested and exercisable, aggregate intrinsic value

^[4]

$ 5,046,733

Expected to vest (in shares)

737,593

Expected to vest, weighted average exercise price (in dollars per share)

$ 24.68

Expected to vest, weighted average contractual term (Year)

4 years 237 days

Total (in shares)

1,047,094

[1]	The aggregate intrinsic value represents the difference between the exercise price and $23.64, the closing price of our stock on December 31, 2018, for all in-the-money options outstanding.
[2]	The aggregate intrinsic value represents the difference between the exercise price and $35.95, the closing price of our stock on December 31, 2019, for all in-the-money options outstanding.
[3]	The aggregate intrinsic value of shares exercised represents the difference between the exercise price and the closing price of our stock on the date of exercise.
[4]	The aggregate intrinsic value represents the difference between the exercise price and $35.95, the closing price of our stock on December 31, 2019, for all in-the-money options vested and exercisable as of that date.

Note 9 - Stockholders' Equity - Summary of RSU Activity (Details) - Restricted Stock Units (RSUs) [Member]

12 Months Ended

Dec. 31, 2019

$ / shares

Outstanding (in shares) | shares

217,895

Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares

$ 21.21

Granted (in shares) | shares

56,567

Granted, weighted average grant date fair value (in dollars per share) | $ / shares

$ 35.41

Vested (in shares) | shares

(61,058)

^[1]

Vested, weighted average grant date fair value (in dollars per share) | $ / shares

$ 18.46

^[1]

Canceled (in shares) | shares

(24,723)

Canceled, weighted average grant date fair value (in dollars per share) | $ / shares

$ 22.19

Outstanding (in shares) | shares

188,681

Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares

$ 26.14

[1]	The number of RSUs vested includes the shares that we withheld on behalf of employees to satisfy minimum statutory tax withholding requirements.

Note 9 - Stockholders' Equity - Summary of Repurchases (Details) - Restricted Stock Units (RSUs) [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Shares of common stock repurchased (in shares)	20,524	21,410
Average per share repurchase price (in dollars per share)	$ 33.28	$ 34.62
Aggregage purchase price (in thousands)	$ 683	$ 741

Note 9 - Stockholders' Equity - Stock-based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Stock-based compensation	$ 2,642	$ 2,349	$ 2,256
Cost of Sales [Member]
Stock-based compensation	310	272	188
Sales [Member]
Stock-based compensation	544	529	403
General and Administrative Expense [Member]
Stock-based compensation	1,509	1,293	1,484
Research and Development Expense [Member]
Stock-based compensation	279	255	181
Share-based Payment Arrangement, Option [Member]
Stock-based compensation	1,580	1,457	1,612
Restricted Stock Units (RSUs) [Member]
Stock-based compensation	$ 1,062	$ 892	$ 644

Note 9 - Stockholders' Equity - Dividend Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Per share amount (in dollars per share)	$ 0.34	$ 0.28	$ 0.22
Quarterly Dividends 1 [Member]
Record date	Apr. 05, 2019	Apr. 05, 2018
Per share amount (in dollars per share)	$ 1,672	$ 1,351
Quarterly Dividends 2 [Member]
Record date	Jun. 06, 2019	Jun. 07, 2018
Per share amount (in dollars per share)	$ 1,672	$ 1,353
Quarterly Dividends 3 [Member]
Record date	Sep. 05, 2019	Sep. 06, 2018
Per share amount (in dollars per share)	$ 1,691	$ 1,369
Quarterly Dividends 4 [Member]
Record date	Dec. 05, 2019	Dec. 06, 2018
Per share amount (in dollars per share)	$ 1,701	$ 1,372

Note 10 - Profit-sharing Plan (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Defined Contribution, Plan Employers Matching Contribution, Annual Vesting Period	6 years
Deferred Profit Sharing [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0.4	$ 0.3	$ 0.2

Note 11 - Segment and Enterprise-wide Disclosures (Details Textual)	12 Months Ended
	Dec. 31, 2019
Number of Operating Segments	1

Note 11 - Segment and Enterprise-wide Disclosures - Net Sales to Unaffiliated Customers by Geography (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net sales	$ 30,170	$ 29,100	$ 29,483	$ 28,479	$ 28,389	$ 24,165	$ 27,020	$ 25,994	$ 117,232	$ 105,568	$ 100,867
UNITED STATES
Net sales									63,130	59,078	58,470
GERMANY
Net sales									12,400	12,445	11,576
Other Countries [Member]
Net sales									$ 41,702	$ 34,045	$ 30,821

Note 11 - Segment and Enterprise-wide Disclosures - Long-term Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Long-term Assets	$ 30,062	$ 14,102
UNITED STATES
Long-term Assets	24,885	11,006
AUSTRALIA
Long-term Assets	1,499	1,460
FRANCE
Long-term Assets	1,089	1,071
GERMANY
Long-term Assets	1,405	430
Other Countries [Member]
Long-term Assets	$ 1,184	$ 135

Note 12 - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash paid for income taxes, net	$ 4,817	$ 5,521	$ 3,146

Note 13 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2019	Oct. 11, 2019
CardioCel and VascuCel Biologic Patches [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 7,800
CardioCel and VascuCel Biologic Patches [Member] \| Audited Carve-Out Financial Statements of the Acquired Business [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	300
CardioCel and VascuCel Biologic Patches [Member] \| Third Holdback [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	2,000
Business Combination, Contingent Consideration, Liability, Total		$ 2,000
CardioCel and VascuCel Biologic Patches [Member] \| Extension of Product Shelf Life from 36 Months to 60 Months in the First Anniversary of Closing Date [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	500
Business Combination, Contingent Consideration, Liability, Total		500
CardioCel and VascuCel Biologic Patches [Member] \| Achievement of Specified Levels of Revenues [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	5,000
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member]
Assets, Fair Value Disclosure	$ 0
Fair Value, Inputs, Level 3 [Member] \| CardioCel and VascuCel Biologic Patches [Member]
Business Combination, Contingent Consideration, Liability, Total		$ 2,000

Note 13 - Fair Value Measurements - Rollforward of the Fair Value as Determined by Level 3 (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Beginning balance	$ 72	$ 1,300	$ 1,320
Additions	1,989
Payments	(309)	(1,199)	(126)
Change in fair value included in earnings	12	(29)	106
Ending balance	$ 1,764	$ 72	$ 1,300

Note 14 - Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total net sales	$ 30,170	$ 29,100	$ 29,483	$ 28,479	$ 28,389	$ 24,165	$ 27,020	$ 25,994	$ 117,232	$ 105,568	$ 100,867
Gross profit	19,908	20,166	20,315	19,464	19,218	17,255	18,992	18,474	79,853	73,939	70,697
Income (loss) from operations	4,928	5,905	5,915	4,435	7,193	4,613	11,541	4,862	21,183	28,209	21,103
Net income	$ 4,613	$ 5,184	$ 4,624	$ 3,513	$ 6,025	$ 4,314	$ 8,751	$ 3,853	$ 17,934	$ 22,943	$ 17,177
Basic:
Basic (in dollars per share)	$ 0.23	$ 0.26	$ 0.23	$ 0.18	$ 0.31	$ 0.22	$ 0.45	$ 0.20	$ 0.91	$ 1.18	$ 0.91
Diluted (in dollars per share)	$ 0.23	$ 0.25	$ 0.23	$ 0.17	$ 0.30	$ 0.21	$ 0.43	$ 0.19	$ 0.88	$ 1.13	$ 0.86
Total net sales	$ 30,170	$ 29,100	$ 29,483	$ 28,479	$ 28,389	$ 24,165	$ 27,020	$ 25,994	$ 117,232	$ 105,568	$ 100,867
Gross profit	19,908	20,166	20,315	19,464	19,218	17,255	18,992	18,474	79,853	73,939	70,697
Income (loss) from operations	4,928	5,905	5,915	4,435	7,193	4,613	11,541	4,862	21,183	28,209	21,103
Net income	$ 4,613	$ 5,184	$ 4,624	$ 3,513	$ 6,025	$ 4,314	$ 8,751	$ 3,853	$ 17,934	$ 22,943	$ 17,177

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Note 15 - Accumulated Other Comprehensive Income (Loss) - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Balance	$ 130,235	$ 109,770	$ 87,500
Balance	148,141	130,235	109,770
AOCI Attributable to Parent [Member]
Balance	(3,900)	(2,289)	(4,583)
Other comprehensive income (loss) before reclassifications	(107)	(1,611)	2,294
Amounts reclassified from accumulated other comprehensive loss
Balance	$ (4,007)	$ (3,900)	$ (2,289)